Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• "I have lost in every facet of my life": the hidden burden of severe asthma.1 passage
• "Scar-cinoma": viewing the fibrotic lung mesenchymal cell in the context of cancer biology.1 passage
• "T2-high" in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin.1 passage
• "You can leave your mask on": effects on cardiopulmonary parameters of different airway protective masks at rest and during maximal exercise.1 passage
• (untitled)11 passages
• 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).1 passage
• 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.1 passage
• 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC).1 passage
• 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.1 passage
• A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use.1 passage
• A European Respiratory Society technical standard: exhaled biomarkers in lung disease.1 passage
• A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression?1 passage
• A comprehensive echocardiographic method for risk stratification in pulmonary arterial hypertension.1 passage
• A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease.1 passage
• A contemporary survival analysis of individuals with cystic fibrosis: a cohort study.1 passage
• A frame of reference for assessing the intensity of exertional dyspnoea during incremental cycle ergometry.1 passage
• A fully automatic deep learning system for COVID-19 diagnostic and prognostic analysis.1 passage
• A genome-wide association study implicates1 passage
• A genome-wide association study of severe asthma exacerbations in Latino children and adolescents.1 passage
• A helper-dependent adenoviral vector rescues CFTR to wild-type functional levels in cystic fibrosis epithelial cells harbouring class I mutations.1 passage
• A high-risk airway mycobiome is associated with frequent exacerbation and mortality in COPD.1 passage
• A joint ERS/ATS policy statement: what constitutes an adverse health effect of air pollution? An analytical framework.1 passage
• A large-scale genome-wide association analysis of lung function in the Chinese population identifies novel loci and highlights shared genetic aetiology with obesity.1 passage
• A longitudinal modelling study estimates acute symptoms of community acquired pneumonia recover to baseline by 10 days.1 passage
• A longitudinal study characterising a large adult primary ciliary dyskinesia population.1 passage
• A major genetic determinant of autoimmune diseases is associated with the presence of autoantibodies in hypersensitivity pneumonitis.1 passage
• A meta-analysis of genome-wide association studies of asthma in Puerto Ricans.1 passage
• A multicentre study of air pollution exposure and childhood asthma prevalence: the ESCAPE project.1 passage
• A multicentre validation of the 1-min sit-to-stand test in patients with COPD.1 passage
• A musical intervention for respiratory comfort during noninvasive ventilation in the ICU.1 passage
• A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.1 passage
• A novel immune biomarker1 passage
• A novel locus for exertional dyspnoea in childhood asthma.1 passage
• A novel piperidine identified by stem cell-based screening attenuates pulmonary arterial hypertension by regulating BMP2 and PTGS2 levels.1 passage
• A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol.1 passage
• A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.1 passage
• A potential therapeutic role for angiotensin-converting enzyme 2 in human pulmonary arterial hypertension.1 passage
• A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays.1 passage
• A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD.1 passage
• A quality-of-life measure for adults with primary ciliary dyskinesia: QOL-PCD.1 passage
• A randomised clinical trial of feedback on inhaler adherence and technique in patients with severe uncontrolled asthma.1 passage
• A randomised controlled trial of the effect of a connected inhaler system on medication adherence in uncontrolled asthmatic patients.1 passage
• A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.1 passage
• A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia.1 passage
• A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma.1 passage
• A randomised trial of high-flow nasal cannula in infants with moderate bronchiolitis.1 passage
• A randomised trial of lung sealant versus medical therapy for advanced emphysema.1 passage
• A randomised trial of prednisolone1 passage
• A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.1 passage
• A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.1 passage
• A real-life comparative effectiveness study into the addition of antibiotics to the management of asthma exacerbations in primary care.1 passage
• A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis.1 passage
• A repeated short educational intervention improves asthma control and quality of life.1 passage
• A review of national guidelines for management of COPD in Europe.1 passage
• A scoring system to predict the elevation of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis.1 passage
• A simple algorithm for the identification of clinical COPD phenotypes.1 passage
• A spatially restricted fibrotic niche in pulmonary fibrosis is sustained by M-CSF/M-CSFR signalling in monocyte-derived alveolar macrophages.1 passage
• A sputum gene expression signature predicts oral corticosteroid response in asthma.1 passage
• A standardised method for interpreting the association between mutations and phenotypic drug resistance in1 passage
• A summary of the new GINA strategy: a roadmap to asthma control.1 passage
• A systematic review of blood biomarkers with individual participant data meta-analysis of matrix-metalloproteinase-7 in IPF.1 passage
• A systematic review of comorbidities and outcomes of adult patients with pleural infection.1 passage
• A systematic review of how patients value COPD outcomes.1 passage
• A systematic review of socioeconomic position in relation to asthma and allergic diseases.1 passage
• A virtual asthma clinic for children: fewer routine outpatient visits, same asthma control.1 passage
• A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome.1 passage
• A-to-I editing of miR-200b-3p in airway cells is associated with moderate-to-severe asthma.1 passage
• Aberrant anti-viral response of natural killer cells in severe asthma.1 passage
• Aberrant epithelial differentiation by cigarette smoke dysregulates respiratory host defence.1 passage
• Absolute values of lung function explain the sex difference in breathlessness in the general population.1 passage
• Accelerated FEV1 passage
• Accelerated decline in lung function in adults with a history of remitted childhood asthma.1 passage
• Accelerated telomere attrition in children and teenagers with α1-antitrypsin deficiency.1 passage
• Accuracy of diagnostic testing in primary ciliary dyskinesia.1 passage
• Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.1 passage
• Acquired resistance to macrolides in1 passage
• Activated protein C inhibits neutrophil migration in allergic asthma: a randomised trial.1 passage
• Activation of immune cell proteasomes in peripheral blood of smokers and COPD patients - implications for therapy.1 passage
• Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.1 passage
• Activin-A is overexpressed in severe asthma and is implicated in angiogenic processes.1 passage
• Acute air pollution exposure alters neutrophils in never-smokers and at-risk humans.1 passage
• Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation.1 passage
• Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm.1 passage
• Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.1 passage
• Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model.1 passage
• Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia.1 passage
• Acute wheeze-specific gene module shows correlation with vitamin D and asthma medication.1 passage
• Adaptive servo ventilation for central sleep apnoea in heart failure: SERVE-HF on-treatment analysis.1 passage
• Addressing unmet needs in understanding asthma mechanisms: From the European Asthma Research and Innovation Partnership (EARIP) Work Package (WP)2 collaborators.1 passage
• Adenotonsillectomy for childhood obstructive sleep apnoea reduces thoraco-abdominal asynchrony but spontaneous apnoea-hypopnoea index normalisation does not.1 passage
• Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma.1 passage
• Adjunctive treatment with oral dexamethasone in non-ICU patients hospitalised with community-acquired pneumonia: a randomised clinical trial.1 passage
• Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.1 passage
• Adult lung function and long-term air pollution exposure. ESCAPE: a multicentre cohort study and meta-analysis.1 passage
• African ancestry, lung function and the effect of genetics.1 passage
• African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.1 passage
• Age at menopause and lung function: a Mendelian randomisation study.1 passage
• Age-adjusted high-sensitivity troponin T cut-off value for risk stratification of pulmonary embolism.1 passage
• Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis.1 passage
• Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics.1 passage
• Air pollution and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA) air-lung study.1 passage
• Air pollution and the development of asthma from birth until young adulthood.1 passage
• Air pollution exposure and lung function until age 16 years: the PIAMA birth cohort study.1 passage
• Air pollution, lung function and COPD: results from the population-based UK Biobank study.1 passage
• Airflow limitation by the Global Lungs Initiative equations in a cohort of very old adults.1 passage
• Airway G-CSF identifies neutrophilic inflammation and contributes to asthma progression.1 passage
• Airway calibre variation is a major determinant of exhaled nitric oxide's ability to capture asthma control.1 passage
• Airway dynamics in COPD patients by within-breath impedance tracking: effects of continuous positive airway pressure.1 passage
• Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma.1 passage
• Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids.1 passage
• Airway inflammation in COPD: progress to precision medicine.1 passage
• Airway microbiome in adult survivors of extremely preterm birth: the EPICure study.1 passage
• Airway microbiota across age and disease spectrum in cystic fibrosis.1 passage
• Airway morphometry in COPD with bronchiectasis: a view on all airway generations.1 passage
• Airway wall thickness associated with forced expiratory volume in 1 second decline and development of airflow limitation.1 passage
• Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.1 passage
• All-oral longer regimens are effective for the management of multidrug resistant tuberculosis in high burden settings.1 passage
• Allergen inhalation generates pro-inflammatory oxidised phosphatidylcholine associated with airway dysfunction.1 passage
• Allergen-induced airway responses.1 passage
• Allergic diseases and long-term risk of autoimmune disorders: longitudinal cohort study and cluster analysis.1 passage
• Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold.1 passage
• Altered exhaled biomarker profiles in children during and after rhinovirus-induced wheeze.1 passage
• Altered neural activity in brain cough suppression networks in cigarette smokers.1 passage
• Altered pulmonary blood volume distribution as a biomarker for predicting outcomes in COVID-19 disease.1 passage
• Alternative inert gas washout outcomes in patients with primary ciliary dyskinesia.1 passage
• Ambient air pollution and pulmonary vascular volume on computed tomography: the MESA Air Pollution and Lung cohort studies.1 passage
• Ambient air pollution, traffic noise and adult asthma prevalence: a BioSHaRE approach.1 passage
• Ambulatory management of secondary spontaneous pneumothorax: a randomised controlled trial.1 passage
• Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma.1 passage
• Amplified canonical transforming growth factor-β signalling1 passage
• An association of particulate air pollution and traffic exposure with mortality after lung transplantation in Europe.1 passage
• An atypical pulmonary fibrosis is associated with co-inheritance of mutations in the calcium binding protein genes1 passage
• An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.1 passage
• An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.1 passage
• An evidence-based, point-of-care tool to guide completion of asthma action plans in practice.1 passage
• An inhaled "bifunctional" dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD.1 passage
• An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in1 passage
• An interferon inducible signature of airway disease from blood gene expression profiling.1 passage
• An international registry for primary ciliary dyskinesia.1 passage
• An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.1 passage
• An official European Respiratory Society statement: pulmonary haemodynamics during exercise.1 passage
• An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features.1 passage
• An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.1 passage
• Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study.1 passage
• Analysis of advanced lung cancer patients diagnosed following emergency admission.1 passage
• Analysis of airway pathology in COPD using a combination of computed tomography, micro-computed tomography and histology.1 passage
• Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients.1 passage
• Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.1 passage
• Angiotensin converting enzyme 2 and angiotensin (1-7) axis in pulmonary arterial hypertension.1 passage
• Annual risk of tuberculosis infection in rural China: a population-based prospective study.1 passage
• Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD.1 passage
• Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma.1 passage
• Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics.1 passage
• Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial.1 passage
• Antibiotic efficacy varies based on the infection model and treatment regimen for1 passage
• Anticoagulant treatment for acute pulmonary embolism: a pathophysiology-based clinical approach.1 passage
• Antimicrobial peptide levels are linked to airway inflammation, bacterial colonisation and exacerbations in chronic obstructive pulmonary disease.1 passage
• Application of transthoracic shear-wave ultrasound elastography in lung lesions.1 passage
• Are smokers "hardening" or rather "softening"? An ecological and multilevel analysis across 28 European Union countries.1 passage
• Artificial intelligence in CT for quantifying lung changes in the era of CFTR modulators.1 passage
• Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests.1 passage
• Artificial intelligence techniques in asthma: a systematic review and critical appraisal of the existing literature.1 passage
• Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database.1 passage
• Assessing global COPD awareness with Google Trends.1 passage
• Assessment of Global Lung Function Initiative (GLI) reference equations for diffusing capacity in relation to respiratory burden in the Swedish CArdioPulmonary bioImage Study (SCAPIS).1 passage
• Assessment of chronic bronchitis and risk factors in young adults: results from BAMSE.1 passage
• Association between adiposity measures and COPD risk in Chinese adults.1 passage
• Association between asthma control trajectories in preschoolers and disease remission.1 passage
• Association between lung cancer somatic mutations and occupational exposure in never-smokers.1 passage
• Association between physical activity and risk of hospitalisation in bronchiectasis.1 passage
• Association between sleep apnoea and pulmonary hypertension in Kyrgyz highlanders.1 passage
• Association between the renin-angiotensin system and chronic lung allograft dysfunction.1 passage
• Association of Early Life Factors with Prematurity-Associated Lung Disease: Prospective Cohort Study.1 passage
• Association of asthma and smoking with lung function impairment in adolescence and early adulthood: the Isle of Wight Birth Cohort Study.1 passage
• Association of dyspnoea, mortality and resource use in hospitalised patients.1 passage
• Association of lung clearance index with survival in individuals with cystic fibrosis.1 passage
• Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalised for bronchiolitis.1 passage
• Association of outdoor temperature with lung function in a temperate climate.1 passage
• Association of short-term ozone and temperature with sleep disordered breathing.1 passage
• Associations between blood eosinophils and decline in lung function among adults with and without asthma.1 passage
• Associations between dietary scores with asthma symptoms and asthma control in adults.1 passage
• Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling.1 passage
• Asthma and Coronavirus Disease 2019 Risk: a systematic review and meta-analysis.1 passage
• Asthma and affective traits in adults: a genetically informative study.1 passage
• Asthma and bronchiectasis exacerbation.1 passage
• Asthma and smoking-induced airway disease without spirometric COPD.1 passage
• Asthma health services utilisation before, during and after pregnancy: a population-based cohort study.1 passage
• Asthma in reproductive-aged women with polycystic ovary syndrome and association with obesity.1 passage
• Asthma inhaler adherence determinants in adults: systematic review of observational data.1 passage
• Asthma medication use in obese and healthy weight asthma: systematic review/meta-analysis.1 passage
• Asthma phenotypes and IgE responses.1 passage
• Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma?1 passage
• Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents.1 passage
• Asthma progression and mortality: the role of inhaled corticosteroids.1 passage
• Asthma, COPD and overlap syndrome: a longitudinal study in young European adults.1 passage
• Asthma, airflow limitation and mortality risk in the general population.1 passage
• Automated closed-loop1 passage
• Automatic1 passage
• Autotitrating external positive end-expiratory airway pressure to abolish expiratory flow limitation during tidal breathing in patients with severe COPD: a physiological study.1 passage
• Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.1 passage
• Awake prone positioning and oxygen therapy in patients with COVID-19: The APRONOX study.1 passage
• Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial.1 passage
• BMPR2 mutation status influences bronchial vascular changes in pulmonary arterial hypertension.1 passage
• Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis.1 passage
• Bacteria-driven peribronchial lymphoid neogenesis in bronchiectasis and cystic fibrosis.1 passage
• Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent.1 passage
• Bacterial load and defective monocyte-derived macrophage bacterial phagocytosis in biomass smoke-related COPD.1 passage
• Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: the initial German experience.1 passage
• Baseline IL-6 is a biomarker for unfavorable tuberculosis treatment outcomes: a multi-site discovery and validation study.1 passage
• Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.1 passage
• Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma.1 passage
• Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.1 passage
• Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.1 passage
• Benefit of treatment of latent tuberculosis infection in individual patients.1 passage
• Benefits of improved air quality on ageing lungs: impacts of genetics and obesity.1 passage
• Benefits of physical activity on COPD hospitalisation depend on intensity.1 passage
• Beryllium-induced lung disease exhibits expression profiles similar to sarcoidosis.1 passage
• Beta-blockers in COPD: time for reappraisal.1 passage
• Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea.1 passage
• BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers.1 passage
• Bioengineered airway epithelial grafts with mucociliary function based on collagen IV- and laminin-containing extracellular matrix scaffolds.1 passage
• Biological therapies in nonsmall cell lung cancer.1 passage
• Biomarker signatures for progressive idiopathic pulmonary fibrosis.1 passage
• Biomarkers for risk of developing active tuberculosis in contacts of TB patients: a prospective cohort study.1 passage
• Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea.1 passage
• Biomarkers of oxidative stress following continuous positive airway pressure withdrawal: data from two randomised trials.1 passage
• Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes.1 passage
• Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study.1 passage
• Blood basophil activation is a reliable biomarker of allergic bronchopulmonary aspergillosis in cystic fibrosis.1 passage
• Blood eosinophil count and risk of pneumonia hospitalisations in individuals with COPD.1 passage
• Blood eosinophil count in the general population: typical values and potential confounders.1 passage
• Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk Samsung Health Study.1 passage
• Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis.1 passage
• Blood eosinophils as a marker of response to inhaled corticosteroids in COPD.1 passage
• Blood granulocyte patterns as predictors of asthma phenotypes in adults from the EGEA study.1 passage
• Blood leukocyte transcriptomes in gram-positive and gram-negative community-acquired pneumonia.1 passage
• Blood pressure response to CPAP treatment in subjects with obstructive sleep apnoea: the predictive value of 24-h ambulatory blood pressure monitoring.1 passage
• Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.1 passage
• Breastfeeding, maternal asthma and wheezing in the first year of life: a longitudinal birth cohort study.1 passage
• Breathlessness in COPD: linking symptom clusters with brain activity.1 passage
• Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: a cohort study.1 passage
• Broadening symptom criteria improves early case identification in SARS-CoV-2 contacts.1 passage
• Bronchial hyperresponsiveness and obesity in middle age: insights from an Australian cohort.1 passage
• Bronchial inflammation and bacterial load in stable COPD is associated with TLR4 overexpression.1 passage
• Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein-60 secretion and protein arginine methyltransferase-1 in fibroblasts.1 passage
• Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis.1 passage
• Bronchodilator response following methacholine-induced bronchoconstriction predicts acute asthma exacerbations.1 passage
• Bronchodilator reversibility in asthma and COPD: findings from three large population studies.1 passage
• Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.1 passage
• Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma.1 passage
• Burden and risk factors for1 passage
• Burden of disease and change in practice in critically ill infants with bronchiolitis.1 passage
• Burden of non-tuberculous mycobacterial pulmonary disease in Germany.1 passage
• Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study.1 passage
• C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD.1 passage
• CAMPHOR score: patient-reported outcomes are improved by pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension.1 passage
• CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.1 passage
• CCR2/CCR5-mediated macrophage-smooth muscle cell crosstalk in pulmonary hypertension.1 passage
• CCSP counterbalances airway epithelial-driven neutrophilic chemotaxis.1 passage
• CD133+ cells in pulmonary arterial hypertension.1 passage
• CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension.1 passage
• COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.1 passage
• COMET: a multicomponent home-based disease-management programme1 passage
• COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension.1 passage
• COPD and risk of venous thromboembolism and mortality in a general population.1 passage
• COPD biomarkers and phenotypes: opportunities for better outcomes with precision imaging.1 passage
• COPD comorbidities network.1 passage
• COVID-19 and pneumothorax: a multicentre retrospective case series.1 passage
• COVID-19: Interim Guidance on Rehabilitation in the Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force.1 passage
• COVID-19: guidance on palliative care from a European Respiratory Society international task force.1 passage
• CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions.1 passage
• CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages.1 passage
• CX3CR1-fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases.1 passage
• CXCR4+ granulocytes reflect fungal cystic fibrosis lung disease.1 passage
• Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees: Statement of the European Respiratory Society and the European Region of the International Union Against Tuberculosis and Lung Disease.1 passage
• Can simvastatin reduce COPD exacerbations? A randomised double-blind controlled study.1 passage
• Can we predict tuberculosis cure? What tools are available?1 passage
• Cancer risk in patients with sleep apnoea following adherent 5-year CPAP therapy.1 passage
• Cardiac function and pulmonary hypertension in Central Asian highlanders at 3250 m.1 passage
• Cardiac sarcoidosis: systematic review of literature on corticosteroid and immunosuppressive therapies.1 passage
• Cardiometabolic correlates of sleep disordered breathing in Andean highlanders.1 passage
• Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation.1 passage
• Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial.1 passage
• Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials.1 passage
• Care in Chronic Obstructive Lung Disease (CAROL): a randomised trial in general practice.1 passage
• Cathepsin B promotes collagen biosynthesis, which drives bronchiolitis obliterans syndrome.1 passage
• Cellular senescence: friend or foe to respiratory viral infections?1 passage
• Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension.1 passage
• Centrally located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumour centrality with dedicated imaging software.1 passage
• Ceramide-1-phosphate inhibits cigarette smoke-induced airway inflammation.1 passage
• Challenges and perspectives in obstructive sleep apnoea: Report by an1 passage
• Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD.1 passage
• Change in the manifestations of asthma and asthma-related traits in childhood: a latent transition analysis.1 passage
• Changes in airway inflammation during pulmonary exacerbations in patients with cystic fibrosis and primary ciliary dyskinesia.1 passage
• Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study.1 passage
• Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies.1 passage
• Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.1 passage
• Changes in treatment for multidrug-resistant tuberculosis according to national income.1 passage
• Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006-2016.1 passage
• Characterisation of Pediatric Pulmonary Hypertensive Vascular Disease from the PPHNet Registry.1 passage
• Characterisation of asthma subgroups associated with circulating YKL-40 levels.1 passage
• Characterisation of children hospitalised with pneumonia in central Vietnam: a prospective study.1 passage
• Characterisation of eppin function: expression and activity in the lung.1 passage
• Characterisation of patients with interstitial pneumonia with autoimmune features.1 passage
• Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation.1 passage
• Characteristics and treatment regimens across ERS SHARP severe asthma registries.1 passage
• Characteristics of effective self-management interventions in patients with COPD: individual patient data meta-analysis.1 passage
• Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?1 passage
• Chest computed tomography-derived low fat-free mass index and mortality in COPD.1 passage
• Chest magnetic resonance imaging for pneumonia diagnosis in outpatients with lower respiratory tract infection.1 passage
• Chest physician-reported, work-related, long-latency respiratory disease in Great Britain.1 passage
• Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting.1 passage
• Childhood asthma- pathogenesis and phenotypes.1 passage
• Childhood maltreatment and lung function: findings from the general population.1 passage
• Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis.1 passage
• Childhood wheezing phenotypes influence asthma, lung function and exhaled nitric oxide fraction in adolescence.1 passage
• Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.1 passage
• Children's Bronchiectasis Education Advocacy and Research Network (Child-BEAR-Net): an ERS Clinical Research Collaboration on improving outcomes of children and adolescents with bronchiectasis.1 passage
• Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease.1 passage
• Chronic effects of air pollution on lung function after lung transplantation in the Systems prediction of Chronic Lung Allograft Dysfunction (SysCLAD) study.1 passage
• Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients.1 passage
• Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.1 passage
• Chronic pulmonary aspergillosis complicating sarcoidosis.1 passage
• Chronic pulmonary aspergillosis: prevalence, favouring pulmonary diseases and prognosis.1 passage
• Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.1 passage
• Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study.1 passage
• Chronic thromboembolic pulmonary hypertension.1 passage
• Chymase: a multifunctional player in pulmonary hypertension associated with lung fibrosis.1 passage
• Cigarette smoke-induced epithelial expression of WNT-5B: implications for COPD.1 passage
• Cigarette smoke-initiated autoimmunity facilitates sensitisation to elastin-induced COPD-like pathologies in mice.1 passage
• Circulating adhesion molecules and subclinical interstitial lung disease: the Multi-Ethnic Study of Atherosclerosis.1 passage
• Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD.1 passage
• Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.1 passage
• Circulating plasma exosomes in obstructive sleep apnoea and reverse dipping blood pressure.1 passage
• Classification and effectiveness of different oxygenation goals in mechanically ventilated critically ill patients: network meta-analysis of randomised controlled trials.1 passage
• Clinical and biological characteristics of the French COBRA cohort of adult subjects with asthma.1 passage
• Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort.1 passage
• Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label.1 passage
• Clinical characteristics and 3-month outcomes in cancer patients with incidental1 passage
• Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China.1 passage
• Clinical considerations in individuals with α1 passage
• Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial.1 passage
• Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.1 passage
• Clinical features of large cell neuroendocrine carcinoma: a population-based overview.1 passage
• Clinical implications of incidental venous thromboembolism in cancer patients.1 passage
• Clinical manifestations in primary ciliary dyskinesia: systematic review and meta-analysis.1 passage
• Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease.1 passage
• Clinical phenotypes in adult patients with bronchiectasis.1 passage
• Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers.1 passage
• Clinical phenotypes of extrapulmonary sarcoidosis: an analysis of a French, multi-ethnic, multicentre cohort.1 passage
• Clinical relevance of right ventricular diastolic stiffness in pulmonary hypertension.1 passage
• Clinical trial design and new therapies for pulmonary arterial hypertension.1 passage
• Clinical utility of fractional exhaled nitric oxide in severe asthma management.1 passage
• Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.1 passage
• Clinically relevant differences in COPD health status: systematic review and triangulation.1 passage
• Cloud algorithm-driven oximetry-based diagnosis of obstructive sleep apnoea in symptomatic habitually snoring children.1 passage
• Cluster and CART analyses identify large subgroups of adults with cystic fibrosis at low risk of 10-year death.1 passage
• Co-methylation analysis in lung tissue identifies pathways for fetal origins of COPD.1 passage
• Co-morbid insomnia and obstructive sleep apnoea is associated with all-cause mortality.1 passage
• Coeliac disease and asthma association in children: the role of antibiotic consumption.1 passage
• Collapse phenomenon during Chartis collateral ventilation assessment.1 passage
• Combined endobronchial and oesophageal endosonography for the diagnosis and staging of lung cancer. European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS).1 passage
• Combined measurement of carbon monoxide and nitric oxide lung transfer does not improve the identification of pulmonary hypertension in systemic sclerosis.1 passage
• Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: the Copenhagen General Population Study.1 passage
• Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.1 passage
• Combining pulmonary and cardiac computed tomography biomarkers for disease-specific risk modelling in lung cancer screening.1 passage
• Commuting mode and pulmonary function in Shanghai, China.1 passage
• Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma.1 passage
• Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.1 passage
• Comorbidities in the management of patients with lung cancer.1 passage
• Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.1 passage
• Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis.1 passage
• Comparison of NHANES III and ERS/GLI 12 for airway obstruction classification and severity.1 passage
• Comparison of different staging methods for COPD in predicting outcomes.1 passage
• Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.1 passage
• Comparison of risk assessment strategies for not-high-risk pulmonary embolism.1 passage
• Comparison of the Dyspnoea-12 and Multidimensional Dyspnoea Profile in people with COPD.1 passage
• Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.1 passage
• Complement C3 and allergic asthma: a cohort study of the general population.1 passage
• Complicated grief after death of a relative in the intensive care unit.1 passage
• Complications following symptom-limited thoracentesis using suction.1 passage
• Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial.1 passage
• Computed tomography quantification of emphysema in people living with HIV and uninfected controls.1 passage
• Computed tomography-based radiomics decodes prognostic and molecular differences in interstitial lung disease related to systemic sclerosis.1 passage
• Concordance between upper and lower airway microbiota in infants with cystic fibrosis.1 passage
• Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea.1 passage
• Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events.1 passage
• Connective tissue diseases, multimorbidity and the ageing lung.1 passage
• Connexin-43 is a promising target for pulmonary hypertension due to hypoxaemic lung disease.1 passage
• Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature.1 passage
• Continuous laryngoscopy quantitates laryngeal behaviour in exercise and recovery.1 passage
• Continuous positive airway pressure effect on visual acuity in patients with type 2 diabetes and obstructive sleep apnoea: a multicentre randomised controlled trial.1 passage
• Continuous positive airway pressure improves blood pressure and serum cardiovascular biomarkers in obstructive sleep apnoea and hypertension.1 passage
• Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension.1 passage
• Contributions of a hand-held fan to self-management of chronic breathlessness.1 passage
• Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.1 passage
• Control theory prediction of resolved Cheyne-Stokes respiration in heart failure.1 passage
• Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial.1 passage
• Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.1 passage
• Correlates and assessment of excess cardiovascular risk in bronchiectasis.1 passage
• Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.1 passage
• Cortical drive to breathe in amyotrophic lateral sclerosis: a dyspnoea-worsening defence?1 passage
• Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.1 passage
• Cost-effectiveness of1 passage
• Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.1 passage
• Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times.2 passages
• Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: evidence from the MIST2 randomised controlled trial.1 passage
• Cough hypersensitivity and suppression in COPD.1 passage
• Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries.1 passage
• Criteria for diagnosis of exercise pulmonary hypertension.1 passage
• Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network.1 passage
• Cross-reactive antibodies against dust mite-derived enolase induce neutrophilic airway inflammation.1 passage
• Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma.1 passage
• Crucial role of fatty acid oxidation in asthmatic bronchial smooth muscle remodelling.1 passage
• Culture of pulmonary artery endothelial cells from pulmonary artery catheter balloon tips: considerations for use in pulmonary vascular disease.1 passage
• Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD.1 passage
• Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19.1 passage
• Cyclophilin inhibitors restrict Middle East respiratory syndrome coronavirus1 passage
• DNA methylation at birth is associated with lung function development until age 26 years.1 passage
• Dampness, mould, onset and remission of adult respiratory symptoms, asthma and rhinitis.1 passage
• Dasatinib increases endothelial permeability leading to pleural effusion.1 passage
• Day-to-day variability of forced oscillatory mechanics for early detection of acute exacerbations in COPD.1 passage
• Dead space: the physiology of wasted ventilation.1 passage
• Decreased IDO1-dependent tryptophan metabolism in aged lung during influenza.1 passage
• Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area.1 passage
• Deep amplicon sequencing for culture-free prediction of susceptibility or resistance to 13 anti-tuberculous drugs.1 passage
• Deep-learning algorithm helps to standardise ATS/ERS spirometric acceptability and usability criteria.1 passage
• Defective bacterial phagocytosis is associated with dysfunctional mitochondria in COPD macrophages.1 passage
• Defining a standard set of patient-centred outcomes for lung cancer.1 passage
• Defining asthma and assessing asthma outcomes using electronic health record data: a systematic scoping review.1 passage
• Defining asthma-COPD overlap syndrome: a population-based study.1 passage
• Defining severe obstructive lung disease in the biologic era: an endotype-based approach.1 passage
• Definition of a COPD self-management intervention: International Expert Group consensus.1 passage
• Definition, discrimination, diagnosis and treatment of central breathing disturbances during sleep.1 passage
• Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.1 passage
• Deleterious impact of Pseudomonas aeruginosa on cystic fibrosis transmembrane conductance regulator function and rescue in airway epithelial cells.1 passage
• Demographics, management and outcome of females and males with acute respiratory distress syndrome in the LUNG SAFE prospective cohort study.1 passage
• Derivation and validation of a clinical prediction rule for thrombolysis-associated major bleeding in patients with acute pulmonary embolism: the BACS score.1 passage
• Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation.1 passage
• Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients.1 passage
• Detection and monitoring of lung inflammation in cystic fibrosis during respiratory tract exacerbation using diffusion-weighted magnetic resonance imaging.1 passage
• Detection of mild cognitive impairment in middle-aged and older adults with obstructive sleep apnoea.1 passage
• Detection of mild cognitive impairment in middle-aged and older adults with obstructive sleep apnoea: does excessive daytime sleepiness play a role?1 passage
• Determinants of lung disease progression measured by lung clearance index in children with cystic fibrosis.1 passage
• Development and external validation of 1- and 2-year mortality prediction models in cystic fibrosis.1 passage
• Development and validation of a deep learning algorithm detecting 10 common abnormalities on chest radiographs.1 passage
• Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis.1 passage
• Development and validation of a simple tool for the assessment of home noninvasive ventilation: the S1 passage
• Development and validation of the Adolescent Asthma Self-Efficacy Questionnaire (AASEQ).1 passage
• Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international multicentre study.1 passage
• Development of a prognostic model of respiratory insufficiency or death in amyotrophic lateral sclerosis.1 passage
• Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?1 passage
• Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support.1 passage
• Diagnosing primary ciliary dyskinesia: an international patient perspective.1 passage
• Diagnosis and outcome of acute respiratory failure in immunocompromised patients after bronchoscopy.1 passage
• Diagnosis of asthma in children: findings from the Swiss Paediatric Airway Cohort.1 passage
• Diagnosis of asthma in children: the contribution of a detailed history and test results.1 passage
• Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism.1 passage
• Diagnosis of pulmonary hypertension.1 passage
• Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study.1 passage
• Diagnostic accuracy of a novel point-of-care urine lipoarabinomannan assay for the detection of tuberculosis among adult outpatients in Zambia: a prospective cross-sectional study.1 passage
• Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.1 passage
• Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV.1 passage
• Diagnostic utility and accuracy of rapid on-site evaluation of bronchoscopic brushings.1 passage
• Dietary antioxidant intake in school age and lung function development up to adolescence.1 passage
• Dietary antioxidants and 10-year lung function decline in adults from the ECRHS survey.1 passage
• Dietary intake of vitamin A, lung function and incident asthma in childhood.1 passage
• Differences between asthma-COPD overlap syndrome and adult-onset asthma.1 passage
• Differences in regional air trapping in current smokers with normal spirometry.1 passage
• Differential DNA methylation in bronchial biopsies between persistent asthma and asthma in remission.1 passage
• Differential blood pressure response to continuous positive airway pressure treatment according to the circadian pattern in hypertensive patients with obstructive sleep apnoea.1 passage
• Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue.1 passage
• Differential response to pulmonary rehabilitation in COPD: multidimensional profiling.1 passage
• Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome.1 passage
• Diffusing Capacity for Carbon Monoxide (DLCO): Association with long-term outcomes after Lung Transplantation in a 20-year longitudinal study.1 passage
• Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up.1 passage
• Digital health for the End TB Strategy: developing priority products and making them work.1 passage
• Digital technologies and adherence in respiratory diseases: the road ahead.1 passage
• Digital-Rapid On-site Examination in Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (DEBUT): a proof of concept study for the application of artificial intelligence in the bronchoscopy suite.1 passage
• Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial.1 passage
• Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network.1 passage
• Disruption of pulmonary lipid homeostasis drives cigarette smoke-induced lung inflammation in mice.1 passage
• Dissecting the genetics of chronic mucus hypersecretion in smokers with and without COPD.1 passage
• Dissimilarity of the gut-lung axis and dysbiosis of the lower airways in ventilated preterm infants.1 passage
• Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures.1 passage
• Do community demographics, environmental characteristics and access to care affect risks of developing ACOS and mortality in people with asthma?1 passage
• Do laboratory challenge tests for occupational asthma represent what happens in the workplace?1 passage
• Dobutamine stress for evaluation of right ventricular reserve in pulmonary arterial hypertension.1 passage
• Docosahexaenoic acid causes rapid pulmonary arterial relaxation via KCa channel-mediated hyperpolarisation in pulmonary hypertension.1 passage
• Does adherence to inhaled corticosteroids predict asthma-related outcomes over time? A cohort study.1 passage
• Does early onset asthma increase childhood obesity risk? A pooled analysis of 16 European cohorts.1 passage
• Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis.1 passage
• Does physical fitness enhance lung function in children and young adults?1 passage
• Does treatment guided by exhaled nitric oxide fraction improve outcomes in subgroups of children with asthma?1 passage
• Donor human leukocyte antigen-G single nucleotide polymorphisms are associated with post-lung transplant mortality.1 passage
• Donor surfactant protein A2 polymorphism and lung transplant survival.1 passage
• Donor-specific and -nonspecific HLA antibodies and outcome post lung transplantation.1 passage
• Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.1 passage
• Doxycycline improves clinical outcomes during cystic fibrosis exacerbations.1 passage
• Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: a multi-centre prospective cohort study in China.1 passage
• Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness1 passage
• Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation.1 passage
• Duration of anticoagulation after isolated pulmonary embolism.1 passage
• Dynamic hyperinflation impairs daily life activity in asthma.1 passage
• Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients.1 passage
• Dyspnoea and respiratory muscle ultrasound to predict extubation failure.1 passage
• Dyspnoea in patients receiving noninvasive ventilation for acute respiratory failure: prevalence, risk factors and prognostic impact: A prospective observational study.1 passage
• Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19.1 passage
• E-cigarette use and respiratory disorders: an integrative review of converging evidence from epidemiological and laboratory studies.1 passage
• E-cigarette vapour enhances pneumococcal adherence to airway epithelial cells.1 passage
• EAN/ERS/ESO/ESRS statement on the impact of sleep disorders on risk and outcome of stroke.1 passage
• EGFR tyrosine kinase inhibitors1 passage
• ERS Clinical Practice Guidelines: High-flow nasal cannula in acute respiratory failure.1 passage
• ERS Statement: A core outcome set for clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations.1 passage
• ERS clinical practice guidelines on treatment of sarcoidosis.1 passage
• ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.1 passage
• ERS statement on chest imaging in acute respiratory failure.1 passage
• ERS statement on chronic thromboembolic pulmonary hypertension.1 passage
• ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension.1 passage
• ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.1 passage
• ERS statement on obstructive sleep disordered breathing in 1- to 23-month-old children.1 passage
• ERS statement on protracted bacterial bronchitis in children.1 passage
• ERS statement on respiratory muscle testing at rest and during exercise.1 passage
• ERS statement on tracheomalacia and bronchomalacia in children.1 passage
• ERS statement: interventional bronchoscopy in children.1 passage
• ERS task force statement: diagnosis and treatment of primary spontaneous pneumothorax.1 passage
• ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests.1 passage
• ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing.1 passage
• ERS/ATS workshop report on respiratory health effects of household air pollution.1 passage
• ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions.1 passage
• ERS/EACTS statement on the management of malignant pleural effusions.1 passage
• ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.1 passage
• ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.1 passage
• ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases.1 passage
• ESR/ERS statement paper on lung cancer screening.1 passage
• ESR/ERS white paper on lung cancer screening.1 passage
• Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.1 passage
• Earlier palliative home care is associated with patient-centred medical resource utilisation and lower costs in the last 30 days before death in COPD: a population-level decedent cohort study.1 passage
• Early childhood growth is associated with lung function at 7 years: a prospective population-based study.1 passage
• Early childhood respiratory morbidity and antibiotic use in ex-preterm infants: a primary care population-based cohort study.1 passage
• Early computed tomography modifications following bronchial thermoplasty in patients with severe asthma.1 passage
• Early exposure to bio-contaminants and asthma up to 10 years of age: results of the HITEA study.1 passage
• Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.1 passage
• Early life exposure to air pollution and incidence of childhood asthma, allergic rhinitis and eczema.1 passage
• Early markers of cystic fibrosis structural lung disease: follow-up of the ACFBAL cohort.1 passage
• Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.1 passage
• Early-life antibiotic use and risk of asthma and eczema: results of a discordant twin study.1 passage
• Early-life risk factors for chronic nonrespiratory diseases.1 passage
• Economic burden of bronchiectasis in Germany.1 passage
• Educational and health outcomes of children treated for asthma: Scotland-wide record linkage study of 683 716 children.1 passage
• Effect of 1 month of zopiclone on obstructive sleep apnoea severity and symptoms: a randomised controlled trial.1 passage
• Effect of aerobic exercise training on asthma in adults: a systematic review and meta-analysis.1 passage
• Effect of asthma and asthma medication on the prognosis of patients with COVID-19.1 passage
• Effect of asthma exacerbation during pregnancy in women with asthma: a population-based cohort study.1 passage
• Effect of continuous positive airway pressure on blood pressure and metabolic profile in women with sleep apnoea.1 passage
• Effect of domiciliary oxygen therapy on exercise capacity and quality of life in patients with pulmonary arterial or chronic thromboembolic pulmonary hypertension: a randomised, placebo-controlled trial.1 passage
• Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study.1 passage
• Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.1 passage
• Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.1 passage
• Effect of long-term corticosteroid treatment on microRNA and gene-expression profiles in COPD.1 passage
• Effect of morphine on breathlessness and exercise endurance in advanced COPD: a randomised crossover trial.1 passage
• Effect of obstructive sleep apnoea on severity and short-term prognosis of acute coronary syndrome.1 passage
• Effect of type and dosage of newly prescribed inhaled corticosteroids on obstructive lung disease and pneumonia hospitalisations in older individuals with asthma, COPD or both: a retrospective study of health administrative data.1 passage
• Effect of upper-airway stimulation for obstructive sleep apnoea on airway dimensions.1 passage
• Effectiveness1 passage
• Effectiveness and outcomes of air travel-related TB incident follow-up: a systematic review.1 passage
• Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.1 passage
• Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.1 passage
• Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.1 passage
• Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.1 passage
• Effectiveness of a specialised breathlessness service for patients with advanced disease in Germany: a pragmatic fast-track randomised controlled trial (BreathEase).1 passage
• Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.1 passage
• Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.1 passage
• Effects of adopting the Global Lung Function Initiative 2017 reference equations on the interpretation of carbon monoxide transfer factor.1 passage
• Effects of antenatal multiple micronutrient supplementation on lung function in mid-childhood: follow-up of a double-blind randomised controlled trial in Nepal.1 passage
• Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.1 passage
• Effects of continuous positive airway pressure on energy balance regulation: a systematic review.1 passage
• Effects of continuous positive airway pressure therapy on left ventricular diastolic function: a randomised, sham-controlled clinical trial.1 passage
• Effects of downhill walking in pulmonary rehabilitation for patients with COPD: a randomised controlled trial.1 passage
• Effects of exercise and airway clearance (positive expiratory pressure) on mucus clearance in cystic fibrosis: a randomised crossover trial.1 passage
• Effects of exercise training on sleep apnoea in patients with coronary artery disease: a randomised trial.1 passage
• Effects of inspiratory muscle training on dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled randomised trial.1 passage
• Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.1 passage
• Effects of quitting cannabis on respiratory symptoms.1 passage
• Effects of short-term continuous positive airway pressure withdrawal on cerebral vascular reactivity measured by blood oxygen level-dependent magnetic resonance imaging in obstructive sleep apnoea: a randomised controlled trial.1 passage
• Effects of suboptimal adherence of CPAP therapy on symptoms of obstructive sleep apnoea: a randomised, double-blind, controlled trial.1 passage
• Effects of the "Living well with COPD" intervention in primary care: a comparative study.1 passage
• Efficacy and safety of TOBI Podhaler in1 passage
• Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.1 passage
• Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.1 passage
• Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF™ 1 - a randomised, Phase II study.1 passage
• Efficacy and safety of inhaled α1-antitrypsin in patients with severe α1-antitrypsin deficiency and frequent exacerbations of COPD.1 passage
• Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.1 passage
• Efficacy of an mHealth intervention to stimulate physical activity in COPD patients after pulmonary rehabilitation.1 passage
• Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function.1 passage
• Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia.1 passage
• Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.1 passage
• Eight novel variants in the1 passage
• Elastase activity on sputum neutrophils correlates with severity of lung disease in cystic fibrosis.1 passage
• Electronic cigarette use in youths: a position statement of the Forum of International Respiratory Societies.1 passage
• Electronic cigarettes: a task force report from the European Respiratory Society.1 passage
• Electronic monitoring of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children.1 passage
• Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients.1 passage
• Elevated lung clearance index in infants with cystic fibrosis shortly after birth.1 passage
• Elevated serum IgE, oral corticosteroid dependence and IL-17/22 expression in highly neutrophilic asthma.1 passage
• Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.1 passage
• EmPHasis-10 as a measure of health-related quality of life in pulmonary arterial hypertension: data from PHAR.1 passage
• EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multicentre study.1 passage
• Emergence of bedaquiline-resistance in a high-burden country of tuberculosis.1 passage
• Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype.1 passage
• Emphysema- and airway-dominant COPD phenotypes defined by standardised quantitative computed tomography.1 passage
• Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury.1 passage
• Endoscopic ultrasound fine-needle aspiration by experienced pulmonologists: a cusum analysis.1 passage
• Endoscopy evaluation to predict oral appliance outcomes in obstructive sleep apnoea.1 passage
• Endothelial cells in the pathogenesis of pulmonary arterial hypertension.1 passage
• Endothelial dysfunction and increased platelet reactivity in patients with acute coronary syndrome and undiagnosed COPD: insights into the SCAP trial.1 passage
• Endothelial eNAMPT amplifies pre-clinical acute lung injury: efficacy of an eNAMPT-neutralising monoclonal antibody.1 passage
• Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?1 passage
• Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD.1 passage
• Environmental fungal sensitisation associates with poorer clinical outcomes in COPD.1 passage
• Eosinophil-derived IL-13 promotes emphysema.1 passage
• Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue.1 passage
• Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC).1 passage
• Epidemiology and health outcomes of sarcoidosis in a universal healthcare population: a cohort study.1 passage
• Epidemiology and impact of chronic bronchitis in chronic obstructive pulmonary disease.1 passage
• Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada.1 passage
• Epidemiology of pleural empyema in English hospitals and the impact of influenza.1 passage
• Epigenetics and pulmonary diseases in the horizon of precision medicine: a review.1 passage
• Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study.1 passage
• Epigenome-wide association study of lung function level and its change.1 passage
• Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.1 passage
• Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.1 passage
• Estimates of the ongoing need for social distancing and control measures post-"lockdown" from trajectories of COVID-19 cases and mortality.1 passage
• Estimating the prevalence of latent tuberculosis in a low-incidence setting: Australia.1 passage
• Ethical obligations for supporting healthcare workers during the COVID-19 pandemic.1 passage
• European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers.1 passage
• European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5-16 years.1 passage
• European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia.1 passage
• European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia.1 passage
• European Respiratory Society guidelines for the management of adult bronchiectasis.1 passage
• European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis.1 passage
• European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD.1 passage
• European Respiratory Society statement on sleep apnoea, sleepiness and driving risk.1 passage
• European Respiratory Society statement on thoracic ultrasound.1 passage
• European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1 passage
• European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations.1 passage
• Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.1 passage
• Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.1 passage
• Evaluation of bronchial wall thickness in asthma using magnetic resonance imaging.1 passage
• Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis.1 passage
• Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia.1 passage
• Evaluation of the airway microbiome in nontuberculous mycobacteria disease.1 passage
• Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018: a record linkage study of the care cascade.1 passage
• Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.1 passage
• Evolution of CT findings after anticoagulant treatment for acute pulmonary embolism in patients with and without an ultimate diagnosis of CTEPH.1 passage
• Evolution of respiratory function in Duchenne muscular dystrophy from childhood to adulthood.1 passage
• Exacerbation action plans for patients with COPD and comorbidities: a randomised controlled trial.1 passage
• Exaggerated BMP4 signalling alters human airway basal progenitor cell differentiation to cigarette smoking-related phenotypes.1 passage
• Excess economic burden of comorbidities in COPD: a 15-year population-based study.1 passage
• Excess medical costs in patients with asthma and the role of comorbidity.1 passage
• Excess mucus viscosity and airway dehydration impact COPD airway clearance.1 passage
• Executive Summary: 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung.1 passage
• Exercise intolerance in chronic thromboembolic pulmonary hypertension after pulmonary angioplasty.1 passage
• Exercise intolerance in comorbid COPD and heart failure: the role of impaired aerobic function.1 passage
• Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis.1 passage
• Exercise right heart catheterisation before and after pulmonary endarterectomy in patients with chronic thromboembolic disease.1 passage
• Exercise training in COPD with exercise-induced desaturation does improve exercise capacity, irrespective of whether supplemental oxygen or air is provided during training.1 passage
• Exercise training in COPD: muscle O1 passage
• Exercise ventilatory inefficiency in mild to end-stage COPD.1 passage
• Exercise, ageing and the lung.1 passage
• Exercise-induced bronchoconstriction and bronchodilation: investigating the effects of age, sex, airflow limitation and FEV1 passage
• Exertional dyspnoea and cortical oxygenation in patients with COPD.1 passage
• Exhaled air dispersion during high-flow nasal cannula therapy1 passage
• Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease.1 passage
• Exhaled breath to screen for malignant pleural mesothelioma: a validation study.1 passage
• Exhaled nitric oxide during infancy as a risk factor for asthma and airway hyperreactivity.1 passage
• Exhaled volatile organic compounds as markers for medication use in asthma.1 passage
• Exhaled volatile organic compounds in adult asthma: a systematic review.1 passage
• Expanded lung T-bet+RORγT+ CD4+ T-cells in sarcoidosis patients with a favourable disease phenotype.1 passage
• Expanding the spectrum of European Respiratory Society official scientific documents: short documents complement clinical practice guidelines, statements and technical standards.1 passage
• Expectation and dyspnoea: the neurobiological basis of respiratory nocebo effects.1 passage
• Experimental dyspnoea interferes with locomotion and cognition: a randomised trial.1 passage
• Exposure to household air pollution over 10 years is related to asthma and lung function decline.1 passage
• Exposure to ultrafine particles and respiratory hospitalisations in five European cities.1 passage
• Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities.1 passage
• External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry.1 passage
• FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis.1 passage
• Factors affecting adherence with treatment advice in a clinical trial of patients with severe asthma.1 passage
• Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection.1 passage
• Familial aggregation and heritability of sarcoidosis: a Swedish nested case-control study.1 passage
• Familial pulmonary arterial hypertension by1 passage
• Fatty airways: implications for obstructive disease.1 passage
• Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia.1 passage
• Feasibility of lung clearance index in a clinical setting in pre-school children.1 passage
• Feasibility of shortening intravenous antibiotic therapy based on bacterial load- a proof of concept randomised controlled trial.1 passage
• Fertility outcomes in asthma: a clinical study of 245 women with unexplained infertility.1 passage
• Fertility treatment among women with asthma: a case-control study of 3689 women with live births.1 passage
• Fevipiprant, an oral prostaglandin DP1 passage
• Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.1 passage
• Fibroblast growth factor 21 predicts outcome in community-acquired pneumonia: secondary analysis of two randomised controlled trials.1 passage
• Fibroblast growth factor 23 and Klotho contribute to airway inflammation.1 passage
• Fibrocyte accumulation in the airway walls of COPD patients.1 passage
• First evaluation of QuantiFERON-TB Gold Plus performance in contact screening.1 passage
• First trimester fetal size and prescribed asthma medication at 15 years of age.1 passage
• First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trial.1 passage
• Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance.1 passage
• Follow-up of patients with uncontrolled asthma: clinical features of asthma patients according to the level of control achieved (the COAS study).1 passage
• Follow-up of pulmonary right-to-left shunt in hereditary haemorrhagic telangiectasia.1 passage
• Forced expiratory flows' contribution to lung function interpretation in schoolchildren.1 passage
• Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation.1 passage
• Fractional exhaled nitric oxide for the management of asthma in adults: a systematic review.1 passage
• Framework for the evaluation of new tests for tuberculosis infection.1 passage
• French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension.1 passage
• French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.1 passage
• Function of monocytes and monocyte-derived macrophages in α1-antitrypsin deficiency.1 passage
• Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes.1 passage
• Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis.1 passage
• Functional assessment and phenotypic heterogeneity of1 passage
• Functional evidence for continued alveolarisation in former preterms at school age?1 passage
• Functional respiratory imaging provides novel insights into the long-term respiratory sequelae of bronchopulmonary dysplasia.1 passage
• Future trends in cystic fibrosis demography in 34 European countries.1 passage
• Gait patterns in COPD: the Rotterdam Study.1 passage
• Gait speed and adverse outcomes following hospitalised exacerbation of COPD.1 passage
• Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study.1 passage
• Gefapixant in two randomised dose-escalation studies in chronic cough.1 passage
• Gender differences in adult-onset asthma: results from the Swiss SAPALDIA cohort study.1 passage
• Gene expression and1 passage
• Genetic analyses in a cohort of children with pulmonary hypertension.1 passage
• Genetic analysis of obstructive sleep apnoea discovers a strong association with cardiometabolic health.1 passage
• Genetic counselling in a national referral centre for pulmonary hypertension.1 passage
• Genetic landscape of adult Langerhans cell histiocytosis with lung involvement.1 passage
• Genetic regulation of1 passage
• Genetic susceptibility to asthma increases the vulnerability to indoor air pollution.1 passage
• Genetics and genomics of pulmonary arterial hypertension.1 passage
• Genome-wide association study in patients with pulmonary1 passage
• Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use.1 passage
• Genomic characterisation of pulmonary subsolid nodules: mutational landscape and radiological features.1 passage
• Genotype alone does not predict the clinical course of SFTPC deficiency in paediatric patients.1 passage
• Germline1 passage
• Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.1 passage
• Global Lung Function Initiative 2012 reference equations for spirometry in the Norwegian population.1 passage
• Global Lung Function Initiative reference equations better describe a middle-aged, healthy French population than the European Community for Steel and Coal values.1 passage
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.1 passage
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.1 passage
• Global and regional trends in COPD mortality, 1990-2010.1 passage
• Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.1 passage
• Glucocorticoid toxicity reduction with Mepolizumab using the glucocorticoid toxicity index.1 passage
• Granularity of1 passage
• Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.1 passage
• Growth and nutritional status, and their association with lung function: a study from the international Primary Ciliary Dyskinesia Cohort.1 passage
• Growth differentiation factor-15 is a predictor of important disease outcomes in patients with COPD.1 passage
• Growth trajectories and asthma/rhinitis in children: a longitudinal study in Taiwan.1 passage
• Guide sheath1 passage
• HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis.1 passage
• Haemodynamic definitions and updated clinical classification of pulmonary hypertension.1 passage
• Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis.1 passage
• Haemodynamically proven pulmonary hypertension in a patient with GATA2 deficiency-associated pulmonary alveolar proteinosis and fibrosis.1 passage
• Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension.1 passage
• Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database.1 passage
• Hallmarks of the ageing lung.1 passage
• Health impacts of anthropogenic biomass burning in the developed world.1 passage
• Health-related quality of life and risk factors associated with spirometric restriction.1 passage
• Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.1 passage
• Healthy1 passage
• Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre cohort study.1 passage
• Helmet non-invasive ventilation compared to facemask non-invasive ventilation and high flow nasal cannula in acute respiratory failure: a systematic review and meta-analysis.1 passage
• Heritability and genome-wide association study of diffusing capacity of the lung.1 passage
• Heterogeneity of treatment response in bronchiectasis clinical trials.1 passage
• Heterogeneity within and between physician-diagnosed asthma and/or COPD: NOVELTY cohort.1 passage
• Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis.1 passage
• Hiatal hernia on thoracic computed tomography in pulmonary fibrosis.1 passage
• High COPD prevalence at high altitude: does household air pollution play a role?1 passage
• High D-dimer levels after stopping anticoagulants in pulmonary embolism with sleep apnoea.1 passage
• High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study.1 passage
• High eosinophil counts predict decline in FEV1 passage
• High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.1 passage
• High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.1 passage
• High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study.1 passage
• Higher serum 25(OH)D concentrations are associated with improved FEV1 passage
• Higher throughput drug screening for rare respiratory diseases: readthrough therapy in primary ciliary dyskinesia.1 passage
• Highly sensitive and specific diagnosis of COVID-19 by reverse transcription multiple cross-displacement amplification-labelled nanoparticles biosensor.1 passage
• Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis.1 passage
• Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial.1 passage
• Home-based maintenance tele-rehabilitation reduces the risk for acute exacerbations of COPD, hospitalisations and emergency department visits.1 passage
• Homeostatic and early-recruited CD1011 passage
• Host Lipidome and Tuberculosis Treatment Failure.1 passage
• Host-microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease.1 passage
• How "healthy" should children be when selecting reference samples for spirometry?1 passage
• How to build a lung: latest advances and emerging themes in lung bioengineering.1 passage
• Human bronchial epithelium orchestrates dendritic cell activation in severe asthma.1 passage
• Human diaphragm atrophy in amyotrophic lateral sclerosis is not predicted by routine respiratory measures.1 passage
• Human intermittent hypoxia-induced respiratory plasticity is not caused by inflammation.1 passage
• Human lipopolysaccharide models provide mechanistic and therapeutic insights into systemic and pulmonary inflammation.1 passage
• Hyperglycaemia in cystic fibrosis adversely affects BK channel function critical for mucus clearance.1 passage
• Hyperpolarised1 passage
• Hypertensive disorders of pregnancy, respiratory outcomes and atopy in childhood.1 passage
• Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies.1 passage
• Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea.1 passage
• Hypoxic vascular response and ventilation/perfusion matching in end-stage COPD may depend on p22phox.1 passage
• ICU outcomes can be predicted by noninvasive muscle evaluation: a meta-analysis.1 passage
• IFN-α/IFN-λ responses to respiratory viruses in paediatric asthma.1 passage
• IL-17A from innate and adaptive lymphocytes contributes to inflammation and damage in cystic fibrosis lung disease.1 passage
• IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.1 passage
• IL-4 subverts mycobacterial containment in1 passage
• IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer.1 passage
• Identification of asthma associated microRNAs in bronchial biopsies.1 passage
• Identification of asthma phenotypes based on extrapulmonary treatable traits.1 passage
• Identification of potentially undiagnosed patients with nontuberculous mycobacterial lung disease using machine learning applied to primary care data in the UK.1 passage
• Identifying early pulmonary arterial hypertension biomarkers in systemic sclerosis: machine learning on proteomics from the DETECT cohort.1 passage
• Identifying obstructive sleep apnoea patients responsive to supplemental oxygen therapy.1 passage
• Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years.1 passage
• Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors.1 passage
• Imaging of pulmonary hypertension in adults: a position paper from the Fleischner Society.1 passage
• Immediate bronchodilator response in FEV1 passage
• Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.1 passage
• Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study.1 passage
• Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.1 passage
• Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort.1 passage
• Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study.1 passage
• Impact of COVID-19 lockdown on adherence to continuous positive airway pressure by obstructive sleep apnoea patients.1 passage
• Impact of CPAP therapy on health-related quality of life in elderly patients with apnoea-hypopnea syndrome: a systematic review of randomised clinical trials.1 passage
• Impact of HIV infection and smoking on lung immunity and related disorders.1 passage
• Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension.1 passage
• Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation.1 passage
• Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.1 passage
• Impact of body mass index on development of nontuberculous mycobacterial pulmonary disease.1 passage
• Impact of donor, recipient and matching on survival after high emergency lung transplantation in France.1 passage
• Impact of immunosuppression on incidence, aetiology and outcome of ventilator-associated lower respiratory tract infections.1 passage
• Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.1 passage
• Impact of lung disease on respiratory impedance in young children with cystic fibrosis.1 passage
• Impact of obstructive sleep apnoea and intermittent hypoxia on blood rheology: a translational study.1 passage
• Impact of obstructive sleep apnoea on insulin resistance in nonobese and obese children.1 passage
• Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression?1 passage
• Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism.1 passage
• Impact of sleep alterations on weaning duration in mechanically ventilated patients: a prospective study.1 passage
• Impact of sleep disordered breathing on behaviour among elementary school-aged children: a cross-sectional analysis of a large community-based sample.1 passage
• Impact of sleep disordered breathing on short-term post-operative outcome after elective coronary artery bypass graft surgery: a prospective observational study.1 passage
• Impact of sleep disturbances on kidney function decline in the elderly.1 passage
• Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis.1 passage
• Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma.1 passage
• Impaired cough suppression in chronic refractory cough.1 passage
• Impaired efferocytosis and neutrophil extracellular trap clearance by macrophages in ARDS.1 passage
• Impaired right ventricular lusitropy is associated with ventilatory inefficiency in pulmonary arterial hypertension.1 passage
• Implementing lung health interventions in low- and middle-income countries: a FRESH AIR systematic review and meta-synthesis.1 passage
• Imprinting of the COPD airway epithelium for dedifferentiation and mesenchymal transition.1 passage
• Improved outcomes in ex-smokers with COPD: a UK primary care observational cohort study.1 passage
• In-depth haemodynamic phenotyping of pulmonary hypertension due to left heart disease.1 passage
• In-hospital and midterm out-hospital complications of adults hospitalised with respiratory syncytial virus infection in France, 2017-2019: an observational study.1 passage
• In-hospital mortality following lung cancer resection: nationwide administrative database.1 passage
• Inadequate assessment of adherence to maintenance medication leads to loss of power and increased costs in trials of severe asthma therapy: results from a systematic literature review and modelling study.1 passage
• Incidence and familial risk of pleural mesothelioma in Sweden: a national cohort study.1 passage
• Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old.1 passage
• Incidence of airflow limitation in subjects 65-100 years of age.1 passage
• Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature.1 passage
• Incidence of non-pulmonary cancer and lung cancer by amount of emphysema and airway wall thickness: a community-based cohort.1 passage
• Incidence of occupational latent tuberculosis infection in South African healthcare workers.1 passage
• Incidence of osteoporosis and fragility fractures in asthma: a UK population-based matched cohort study.1 passage
• Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis.1 passage
• Incidence of rhinitis and asthma related to welding in Northern Europe.1 passage
• Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN.1 passage
• Incident opioid drug use and adverse respiratory outcomes among older adults with COPD.1 passage
• Increase in circulating ACE-positive endothelial microparticles during acute lung injury.1 passage
• Increased IgA production by B-cells in COPD via lung epithelial interleukin-6 and TACI pathways.1 passage
• Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes.1 passage
• Increased alveolar soluble annexin V promotes lung inflammation and fibrosis.1 passage
• Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg1 passage
• Increased incidence of inflammatory bowel disease in Québec residents with airway diseases.1 passage
• Increased liver stiffness in patients with severe sleep apnoea and metabolic comorbidities.1 passage
• Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study.1 passage
• Increased respiratory symptoms in COPD patients living in the vicinity of livestock farms.1 passage
• Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.1 passage
• Increasing burden of noninfectious lung disease in persons living with HIV: a 7-year study using the French nationwide hospital administrative database.1 passage
• Individualised risk in patients undergoing lung volume reduction surgery: the Glenfield BFG score.1 passage
• Indoor air quality, ventilation and respiratory health in elderly residents living in nursing homes in Europe.1 passage
• Indoor bacteria and asthma in adults: a multicentre case-control study within ECRHS II.1 passage
• Inducible laryngeal obstruction: an official joint European Respiratory Society and European Laryngological Society statement.1 passage
• Inequalities in lung cancer: a world of EGFR.1 passage
• Infant nasal nitric oxide over time: natural evolution and impact of respiratory tract infection.1 passage
• Infant respiratory infections and later respiratory hospitalisation in childhood.1 passage
• Infantile respiratory syncytial virus and human rhinovirus infections: respective role in inception and persistence of wheezing.1 passage
• Inflammatory bowel disease and risk of mortality in COPD.1 passage
• Inflammatory bowel diseases, chronic liver diseases and the lung.1 passage
• Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions.1 passage
• Influenza virus infection increases ACE2 expression and shedding in human small airway epithelial cells.1 passage
• Influenza virus-induced lung injury: pathogenesis and implications for treatment.1 passage
• Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a1 passage
• Inhaled corticosteroid use and the incidence of lung cancer in COPD.1 passage
• Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study.1 passage
• Inhaled corticosteroids in COPD: friend or foe?1 passage
• Inhaled corticosteroids in COPD: the clinical evidence.1 passage
• Inhaled diesel exhaust alters the allergen-induced bronchial secretome in humans.1 passage
• Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations.1 passage
• Initial dual oral combination therapy in pulmonary arterial hypertension.1 passage
• Innate lymphoid cells in isocyanate-induced asthma: role of microRNA-155.1 passage
• Innate lymphoid cells in the upper airways: importance of CD117 and IL-1RI expression.1 passage
• Inspiratory muscle training does not improve clinical outcomes in 3-week COPD rehabilitation: results from a randomised controlled trial.1 passage
• Insulin resistance modifies the association between obesity and current asthma in adults.1 passage
• Intake of1 passage
• Integration of multi-omics datasets enables molecular classification of COPD.1 passage
• Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension.1 passage
• Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.1 passage
• Intensive care in thoracic oncology.1 passage
• Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension.1 passage
• Inter-test reproducibility of the lung clearance index measured by multiple breath washout.1 passage
• Interaction between asthma and smoking increases the risk of adult airway obstruction.1 passage
• Interaction between the DNAH9 gene and early smoke exposure in bronchial hyperresponsiveness.1 passage
• Interaction effect of psychological distress and asthma control on productivity loss?1 passage
• Intercostal vessel screening prior to pleural interventions by the respiratory physician: a prospective study of real world practice.1 passage
• Interdisciplinary COPD intervention in primary care: a cluster randomised controlled trial.1 passage
• Interleukin-15 is associated with disease severity in viral bronchiolitis.1 passage
• Interleukin-1α drives the dysfunctional cross-talk of the airway epithelium and lung fibroblasts in COPD.1 passage
• Intermittent hypoxia in obstructive sleep apnoea mediates insulin resistance through adipose tissue inflammation.1 passage
• International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT).1 passage
• International consensus guideline for reporting transmission electron microscopy results in the diagnosis of primary ciliary dyskinesia (BEAT PCD TEM Criteria).1 passage
• Interplay between cigarette smoking and pulmonary reverse lipid transport.1 passage
• Interstitial lung disease increases susceptibility to and severity of COVID-19.1 passage
• Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review.1 passage
• Interventions to modify physical activity in patients with COPD: a systematic review.1 passage
• Intra-breath measures of respiratory mechanics in healthy African infants detect risk of respiratory illness in early life.1 passage
• Intragraft donor-specific anti-HLA antibodies in phenotypes of chronic lung allograft dysfunction.1 passage
• Intrapulmonary airway smooth muscle is hyperreactive with a distinct proteome in asthma.1 passage
• Intravenous magnesium sulfate for acute wheezing in young children: a randomised double-blind trial.1 passage
• Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial.1 passage
• Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.1 passage
• Introduction to precision medicine in COPD.1 passage
• Investigating unilateral pleural effusions: the role of cytology.1 passage
• Involvement of CFTR in the pathogenesis of pulmonary arterial hypertension.1 passage
• Is CRP-guided antibiotic treatment a safe way to reduce antibiotic use in severe hospitalised patients with exacerbations of COPD?1 passage
• Is fluid overload a target to treat sleep disordered breathing in patients with end-stage renal disease, and what are the underlying mechanisms?1 passage
• Is parent-child bed-sharing a risk for wheezing and asthma in early childhood?1 passage
• Is ventilation heterogeneity related to asthma control?1 passage
• JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk.1 passage
• Joint effect of airflow limitation and emphysema on postoperative outcomes in early-stage nonsmall cell lung cancer.1 passage
• Kidney function and obstructive lung disease: a bidirectional Mendelian randomisation study.1 passage
• King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference.1 passage
• Laboratory animal allergy is preventable in modern research facilities.1 passage
• Laboratory diagnosis of pneumonia in the molecular age.1 passage
• Laboratory-confirmed respiratory infections as triggers for acute myocardial infarction and stroke: a self-controlled case series analysis of national linked datasets from Scotland.1 passage
• Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre.1 passage
• Large trials, new knowledge: the changing face of COPD management.1 passage
• Late-onset "acute fibrinous and organising pneumonia" impairs long-term lung allograft function and survival.1 passage
• Latent tuberculosis infection in healthcare workers in low- and middle-income countries: an updated systematic review.1 passage
• Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.1 passage
• Leptin signalling system as a target for pulmonary arterial hypertension therapy.1 passage
• Life-course socioeconomic disadvantage and lung function: a multicohort study of 70 496 individuals.1 passage
• Lifting dyspnoea invisibility: COVID-19 face masks, the experience of breathing discomfort, and improved lung health perception - a French nationwide survey.1 passage
• Light-emitting diode fluorescence microscopy for tuberculosis diagnosis: a meta-analysis.1 passage
• Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study.1 passage
• Linking clinical phenotypes of chronic lung allograft dysfunction to changes in lung structure.1 passage
• Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD.1 passage
• Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study.1 passage
• Living with breathlessness: a systematic literature review and qualitative synthesis.1 passage
• Long-term Outcomes of Adult Pulmonary Langerhans Cell Histiocytosis: A Prospective Cohort.1 passage
• Long-term air pollution and road traffic noise exposure and COPD: the Danish Nurse Cohort.1 passage
• Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.1 passage
• Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial.1 passage
• Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD.1 passage
• Long-term effects of severe acute malnutrition on lung function in Malawian children: a cohort study.1 passage
• Long-term efficacy and effectiveness of a behavioural and community-based exercise intervention (Urban Training) to increase physical activity in patients with COPD: a randomised controlled trial.1 passage
• Long-term exposure to low-level air pollution and incidence of asthma: the ELAPSE project.1 passage
• Long-term modulation of airway remodeling in severe asthma following bronchial thermoplasty.1 passage
• Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.1 passage
• Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies.1 passage
• Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.1 passage
• Long-term prognosis of new adult-onset asthma in obese patients.1 passage
• Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study.1 passage
• Long-term trends of asthma, allergic rhinitis and atopic eczema in young Finnish men: a retrospective analysis, 1926-2017.1 passage
• Long-term volume-targeted pressure-controlled ventilation: sense or nonsense?1 passage
• Longitudinal assessment of airway responsiveness from 1 month to 18 years in the PIAF birth cohort.1 passage
• Longitudinal course of clinical lung clearance index in children with cystic fibrosis.1 passage
• Low physical functioning and impaired performance of activities of daily life in COVID-19 patients who survived hospitalisation.1 passage
• Low uptake of palliative care for COPD patients within primary care in the UK.1 passage
• Low-cost, easy-to-build noninvasive pressure support ventilator for under-resourced regions: open source hardware description, performance and feasibility testing.1 passage
• Low-dose chest computed tomographic screening and invasive diagnosis of pulmonary nodules for lung cancer in never-smokers.1 passage
• Low-dose computed tomography for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study.1 passage
• Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients.1 passage
• Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension.1 passage
• Lower lung function associates with cessation of menstruation: UK Biobank data.1 passage
• Lung cancer staging: a concise update.1 passage
• Lung cancer survival in Norway, 1997-2011: from nihilism to optimism.1 passage
• Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations.1 passage
• Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation.1 passage
• Lung function and cardiovascular disease: a two-sample Mendelian randomisation study.1 passage
• Lung function decline in asthma patients with elevated bronchial CD8, CD4 and CD3 cells.1 passage
• Lung function in children in relation to ethnicity, physique and socioeconomic factors.1 passage
• Lung function in patients with primary ciliary dyskinesia: an iPCD Cohort study.1 passage
• Lung function trajectory in progressive fibrosing interstitial lung disease.1 passage
• Lung function, forced expiratory volume in 1 s decline and COPD hospitalisations over 44 years of follow-up.1 passage
• Lung inhomogeneities, inflation and [18F]2-fluoro-2-deoxy-D-glucose uptake rate in acute respiratory distress syndrome.1 passage
• Lung microbiome dynamics in COPD exacerbations.1 passage
• Lung transplantation after allogeneic stem cell transplantation: a pan-European experience.1 passage
• Lung transplantation for acute respiratory distress syndrome - a retrospective European Cohort Study.1 passage
• Lung transplantation for sarcoidosis: outcome and prognostic factors.1 passage
• Lung volumes predict survival in patients with chronic lung allograft dysfunction.1 passage
• Machine learning can predict disease manifestations and outcomes in lymphangioleiomyomatosis.1 passage
• Macitentan in pulmonary hypertension due to left ventricular dysfunction.1 passage
• Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.1 passage
• Macrolide combination therapy for patients hospitalised with community-acquired pneumonia? An individualised approach supported by machine learning.1 passage
• Macrophage activation, age and sex effects of immunometabolism in obese asthma.1 passage
• Macrophage dysfunction in the pathogenesis and treatment of asthma.1 passage
• Macrophage-derived IL-6 trans-signaling as a novel target in the pathogenesis of bronchopulmonary dysplasia.1 passage
• Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.1 passage
• Management appropriateness and outcomes of patients with acute pulmonary embolism.1 passage
• Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.1 passage
• Management of EGFR mutated nonsmall cell lung carcinoma patients.1 passage
• Management of bronchiectasis in adults.1 passage
• Management of continuous positive airway pressure treatment compliance using telemonitoring in obstructive sleep apnoea.1 passage
• Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline.1 passage
• Management of incidental pulmonary embolism.1 passage
• Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries.1 passage
• Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry.1 passage
• Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline.1 passage
• Management of stage I and II nonsmall cell lung cancer.1 passage
• Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.1 passage
• Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.1 passage
• Markers of neutrophil extracellular traps predict adverse outcome in community-acquired pneumonia: secondary analysis of a randomised controlled trial.1 passage
• Mast cells are associated with exacerbations and eosinophilia in children with severe asthma.1 passage
• Matching-adjusted indirect comparison of benralizumab1 passage
• Maternal 17q21 genotype influences prenatal vitamin D effects on offspring asthma/recurrent wheeze.1 passage
• Maternal age at delivery, lung function and asthma in offspring: a population-based survey.1 passage
• Maternal antibiotic use during pregnancy and asthma in children: population-based cohort study and sibling design.1 passage
• Maternal blood pressure and hypertensive disorders during pregnancy and childhood respiratory morbidity: the Generation R Study.1 passage
• Maternal body mass index, neonatal lung function and respiratory symptoms in childhood.1 passage
• Maternal diet in pregnancy and child's respiratory outcomes: an individual participant data meta-analysis of 18 000 children.1 passage
• Maternal dietary antioxidant intake in pregnancy and childhood respiratory and atopic outcomes: birth cohort study.1 passage
• Maternal intake of sugar during pregnancy and childhood respiratory and atopic outcomes.1 passage
• Maternal smoking during pregnancy affects adult onset of asthma in offspring: a follow up from birth to age 46 years.1 passage
• Maternal vitamin D and E intakes during pregnancy are associated with asthma in children.1 passage
• Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis.1 passage
• Maximal exercise capacity in patients with obstructive sleep apnoea syndrome: a systematic review and meta-analysis.1 passage
• Maximal mid-expiratory flow detects early lung disease in α1 passage
• Mean nocturnal respiratory rate predicts cardiovascular and all-cause mortality in community-dwelling older men and women.1 passage
• Measurement of tidal breathing flows in infants using impedance pneumography.1 passage
• Mechanical circulatory support in refractory cardiogenic shock due to influenza virus-related myocarditis.1 passage
• Mechanical ventilation promotes lung tumor spread by modulation of cholesterol cell content.1 passage
• Mechanisms of development of multimorbidity in the elderly.1 passage
• Mechanisms of exertional dyspnoea in symptomatic smokers without COPD.1 passage
• Mechanisms of orthopnoea in patients with advanced COPD.1 passage
• Mechanistic insight into the function of the microbiome in lung diseases.1 passage
• Mediastinal staging by videomediastinoscopy in clinical N1 non-small cell lung cancer: a prospective multicentre study.1 passage
• Mediating pathways from central obesity to childhood asthma: a population-based longitudinal study.1 passage
• Medication adherence and the risk of severe asthma exacerbations: a systematic review.1 passage
• Mediterranean diet during pregnancy and childhood respiratory and atopic outcomes: birth cohort study.1 passage
• Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life.1 passage
• Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension.1 passage
• Mendelian randomisation and experimental medicine approaches to IL-6 as a drug target in PAH.1 passage
• Mepolizumab effectiveness and identification of super-responders in severe asthma.1 passage
• Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme.1 passage
• Mesenchymal Stromal (stem) Cell (MSC) therapy modulates miR-193b-5p expression to attenuate sepsis-induced acute lung injury.1 passage
• Mesenchymal stem cells enhance NOX2-dependent reactive oxygen species production and bacterial killing in macrophages during sepsis.1 passage
• Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS.1 passage
• Meta-analysis of airway epithelium gene expression in asthma.1 passage
• Metabolic re-patterning in COPD airway smooth muscle cells.1 passage
• Metabolomic analyses reveals new stage-specific features of the COVID-19.1 passage
• Metabolomic biomarkers predictive of early structural lung disease in cystic fibrosis.1 passage
• Metabolomics analysis identifies different metabotypes of asthma severity.1 passage
• Metabolomics analysis identifies sex-associated metabotypes of oxidative stress and the autotaxin-lysoPA axis in COPD.1 passage
• Methionine supplementation for multi-organ dysfunction in MetRS-related pulmonary alveolar proteinosis.1 passage
• Methotrexate and rheumatoid arthritis associated interstitial lung disease.1 passage
• Microarray analysis in pulmonary hypertension.1 passage
• Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension.1 passage
• Mild pulmonary hypertension and premature mortality among 154 956 men and women undergoing routine echocardiography.1 passage
• Mindfulness-based cognitive therapy in COPD: a cluster randomised controlled trial.1 passage
• Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study.1 passage
• Minimal clinically important differences in average, best, worst and current intensity and unpleasantness of chronic breathlessness.1 passage
• Missed opportunity? Worsening breathlessness as a harbinger of death: a cohort study.1 passage
• Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis.1 passage
• Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis.1 passage
• Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.1 passage
• Molecular and clinical diseasome of comorbidities in exacerbated COPD patients.1 passage
• Molecular biomarkers for lung adenocarcinoma.1 passage
• Monitoring asthma in children.1 passage
• Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.1 passage
• Monocytes in sarcoidosis are potent tumour necrosis factor producers and predict disease outcome.1 passage
• Monocytes inhibit NK activity1 passage
• Morbidity and mortality in carriers of the cystic fibrosis mutation1 passage
• More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China.1 passage
• Morphine alters respiratory control but not other key obstructive sleep apnoea phenotypes: a randomised trial.1 passage
• Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases.1 passage
• Mortality among patients with pleural effusion undergoing thoracentesis.1 passage
• Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.1 passage
• Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures.1 passage
• Mortality trends in pulmonary arterial hypertension in canada: a temporal analysis of survival per ESC/ERS Guideline Era.1 passage
• Moving target: shifting the focus to pulmonary sarcoidosis as an autoimmune spectrum disorder.1 passage
• Multi-level differential network analysis of COPD exacerbations.1 passage
• Multi-omic molecular profiling of lung cancer in COPD.1 passage
• Multi-omics links IL-6 trans-signalling with neutrophil extracellular trap formation and1 passage
• Multi-omics profiling predicts allograft function after lung transplantation.1 passage
• Multicentre chest computed tomography standardisation in children and adolescents with cystic fibrosis: the way forward.1 passage
• Multicentre observational screening survey for the detection of CTEPH following pulmonary embolism.1 passage
• Multidimensional Dyspnea Profile: an instrument for clinical and laboratory research.1 passage
• Multidrug-resistant tuberculosis around the world: what progress has been made?1 passage
• Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method.1 passage
• Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia.1 passage
• Multimorbidity medications and poor asthma prognosis.1 passage
• Mycoplasma pneumoniae carriage evades induction of protective mucosal antibodies.1 passage
• Myeloid cell-specific deletion of inducible nitric oxide synthase protects against smoke-induced pulmonary hypertension in mice.1 passage
• Myeloperoxidase oxidation of methionine associates with early cystic fibrosis lung disease.1 passage
• Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype.1 passage
• NADPH oxidase DUOX1 sustains TGF-β1 signalling and promotes lung fibrosis.1 passage
• NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung.1 passage
• NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD.1 passage
• Nanoparticle diffusion in spontaneously expectorated sputum as a biophysical tool to probe disease severity in COPD.1 passage
• Nasopharyngeal gene expression, a novel approach to study the course of respiratory syncytial virus infection.1 passage
• National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.1 passage
• Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in the Netherlands.1 passage
• Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion.1 passage
• Natural history of1 passage
• Natural history of sleep disordered breathing in prepubertal children transitioning to adolescence.1 passage
• Natural variability of lung function in young healthy school children.1 passage
• Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma.1 passage
• Nebulised colistin for ventilator-associated pneumonia prevention.1 passage
• Nebulised liposomal-amphotericin-B as maintenance therapy in ABPA: a randomised, multicentre, trial.1 passage
• Needle-based confocal laser endomicroscopy for real-time diagnosing and staging of lung cancer.1 passage
• Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.1 passage
• Nestin promotes pulmonary fibrosis1 passage
• Nestin-expressing vascular wall cells drive development of pulmonary hypertension.1 passage
• Neural respiratory drive and breathlessness in COPD.1 passage
• Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients.1 passage
• Neurohormonal modulation in pulmonary arterial hypertension.1 passage
• Neuropeptide regulation of secretion and inflammation in human airway gland serous cells.1 passage
• Neurophysiological mechanisms of exertional dyspnoea in fibrotic interstitial lung disease.1 passage
• Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.1 passage
• Neutrophil dysfunction in bronchiectasis: an emerging role for immunometabolism.1 passage
• Neutrophil proteases alter the interleukin-22-receptor-dependent lung antimicrobial defence.1 passage
• Neutrophilic inflammation in asthma and defective epithelial translational control.1 passage
• New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.1 passage
• New potential diagnostic biomarkers for pulmonary hypertension.1 passage
• Newborn DNA-methylation, childhood lung function, and the risks of asthma and COPD across the life course.1 passage
• Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.1 passage
• Nitrogen dioxide increases the risk of mortality in idiopathic pulmonary fibrosis.1 passage
• No added value of interferon-γ release to a prediction model for childhood tuberculosis.1 passage
• No impact of passive smoke on the somatic profile of lung cancers in never-smokers.1 passage
• No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.1 passage
• Nocturnal cerebral hypoxia in obstructive sleep apnoea: a randomised controlled trial.1 passage
• Non-anthropogenic dust exposure and asthma medication purchase in children.1 passage
• Non-tuberculous mycobacterial pulmonary disease.1 passage
• Nonadherence in the era of severe asthma biologics and thermoplasty.1 passage
• Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease.1 passage
• Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation.1 passage
• Noninvasive evaluation of pulmonary artery pressure during exercise: the importance of right atrial hypertension.1 passage
• Noninvasive identification of left-sided heart failure in a population suspected of pulmonary arterial hypertension.1 passage
• Nonspecific interstitial pneumonia: survival is influenced by the underlying cause.1 passage
• Normal spirometry predictive values for the Western Indian adult population.1 passage
• Normative data for multiple breath washout outcomes in school-aged Caucasian children.1 passage
• Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China.1 passage
• Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension.1 passage
• Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells.1 passage
• Novel avenues to approach non-CPAP therapy and implement comprehensive OSA care.1 passage
• Novel concepts in airway inflammation and remodelling in asthma.1 passage
• Novel drugs against tuberculosis: a clinician's perspective.1 passage
• Novel magnetic resonance technique for functional imaging of cystic fibrosis lung disease.1 passage
• Novel mechanisms of action contributing to Benralizumab's potent anti-eosinophilic activity.1 passage
• Obesity as a susceptibility factor to indoor particulate matter health effects in COPD.1 passage
• Observing dyspnoea in others elicits dyspnoea, negative affect and brain responses.1 passage
• Obstructive respiratory events and premature atrial contractions after cardioversion.1 passage
• Obstructive sleep apnoea and cognitive decline in mild-to-moderate Alzheimer's disease.1 passage
• Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis.1 passage
• Obstructive sleep apnoea and the progression of thoracic aortic aneurysm: a prospective cohort study.1 passage
• Obstructive sleep apnoea and venous thromboembolism: pathophysiological links and clinical implications.1 passage
• Obstructive sleep apnoea as a risk factor for incident metabolic syndrome: a joined Episono and HypnoLaus prospective cohorts study.1 passage
• Obstructive sleep apnoea in the elderly: role of continuous positive airway pressure treatment.1 passage
• Obstructive sleep apnoea in the general population: highly prevalent but minimal symptoms.1 passage
• Obstructive sleep apnoea is not a risk factor for incident hospitalised depression: a historical cohort study.1 passage
• Obstructive sleep apnoea treatment and blood pressure: which phenotypes predict a response? A systematic review and meta-analysis.1 passage
• Obstructive sleep disordered breathing in 2- to 18-year-old children: diagnosis and management.1 passage
• Occupational exposure to disinfectants and asthma control in US nurses.1 passage
• Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.1 passage
• Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function.1 passage
• Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.1 passage
• Oestrogen-mediated upregulation of the Mas receptor contributes to sex differences in acute lung injury and lung vascular barrier regulation.1 passage
• Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry.1 passage
• Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians.1 passage
• Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure.1 passage
• Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.1 passage
• Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma.1 passage
• Omics-based tracking of1 passage
• Ongoing challenges to understanding multidrug- and rifampicin-resistant tuberculosis in children1 passage
• Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids.1 passage
• Optimising experimental research in respiratory diseases: an ERS statement.1 passage
• Optimising pyrazinamide for the treatment of tuberculosis.1 passage
• Oral corticosteroid prescription patterns for asthma in France, Germany, Italy and the UK.1 passage
• Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis.1 passage
• Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.1 passage
• Oronasal mask versus helmet in acute hypercapnic respiratory failure.1 passage
• Oseltamivir and influenza-related complications in children: a retrospective cohort in primary care.1 passage
• Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study.1 passage
• Outbreak of pre- and extensively drug-resistant tuberculosis in northern Italy: urgency of cross-border, multidimensional, surveillance systems.1 passage
• Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism.1 passage
• Outcome of acute hypoxaemic respiratory failure: insights from the LUNG SAFE Study.1 passage
• Outcome of incidentally detected airway nodules.1 passage
• Outcome of patients with right heart thrombi: the Right Heart Thrombi European Registry.1 passage
• Outcomes in coronary artery disease patients with sleepy obstructive sleep apnoea on CPAP.1 passage
• Outcomes of1 passage
• Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs.1 passage
• Outcomes of β-blocker use in pulmonary arterial hypertension: a propensity-matched analysis.1 passage
• Outcomes over the first two years of treatment with mepolizumab in severe asthma.1 passage
• Outdoor air pollution and the burden of childhood asthma across Europe.1 passage
• Outdoor air pollution, exhaled 8-isoprostane and current asthma in adults: the EGEA study.1 passage
• Overuse of short-acting β1 passage
• Oxidative stress biomarkers and asthma characteristics in adults of the EGEA study.1 passage
• Oxygen compared to air during exercise training in COPD with exercise-induced desaturation.1 passage
• Oxygen desaturation in 6-min walk test is a risk factor for adverse outcomes in COPD.1 passage
• Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey.1 passage
• Oxygen sensing and signal transduction in hypoxic pulmonary vasoconstriction.1 passage
• PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension.1 passage
• PET/CT features of extrapulmonary tuberculosis at first clinical presentation: a cross-sectional observational1 passage
• PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia.1 passage
• Paediatric cohort studies on lower respiratory diseases and their reporting quality: systematic review of the year 2018.1 passage
• Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.1 passage
• Pain control in thoracic oncology.1 passage
• Palatal prolapse as a signature of expiratory flow limitation and inspiratory palatal collapse in patients with obstructive sleep apnoea.1 passage
• Palliative care needs in COPD patients with or without cancer: an epidemiological study.1 passage
• Partitioning of pulmonary vascular resistances in group 2 pulmonary hypertension: insightful suggestions for bridging haemodynamics to underlying mechanisms.1 passage
• Passive smoking in relation to lung cancer incidence and histologic types in Norwegian adults: the HUNT study.1 passage
• Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia.1 passage
• Pathogenesis of COVID-19-induced ARDS: implications for an ageing population.1 passage
• Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH.1 passage
• Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.1 passage
• Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update.1 passage
• Patient characteristics, biomarkers, and exacerbation risk in severe, uncontrolled asthma.1 passage
• Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial.1 passage
• Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohort.1 passage
• Patient-reported outcome measures in the recovery of adults hospitalised with community-acquired pneumonia: a systematic review.1 passage
• Patterns and determinants of exhaled nitric oxide trajectories in schoolchildren over a 7-year period.1 passage
• Patterns of healthcare utilisation for respiratory complications of adults with neuromuscular disease: a population study.1 passage
• Patterns of regional lung physiology in cystic fibrosis using ventilation magnetic resonance imaging and multiple-breath washout.1 passage
• Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza.1 passage
• Pedometers to enhance physical activity in COPD: a randomised controlled trial.1 passage
• Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding.1 passage
• Performance of immune-based and microbiological tests in children with tuberculosis meningitis in Europe: a multicentre Paediatric Tuberculosis Network European Trials Group (ptbnet) study.1 passage
• Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.1 passage
• Perinatal air pollution exposure and development of asthma from birth to age 10 years.1 passage
• Periostin: contributor to abnormal airway epithelial function in asthma?1 passage
• Peripheral blood leukocyte telomere length is associated with survival of sepsis patients.1 passage
• Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis.1 passage
• Persistent exercise intolerance after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.1 passage
• Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD.1 passage
• Personal exposure to air pollution and respiratory health of COPD patients in London.1 passage
• Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public.1 passage
• Perspectives of patients and healthcare professionals on mHealth for asthma self-management.1 passage
• Perspectives on neuroinflammation contributing to chronic cough.1 passage
• Perspectives on palliative oxygen for breathlessness: systematic review and meta-synthesis.1 passage
• Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis.1 passage
• Pharmacists and medication adherence in asthma: a systematic review and meta-analysis.1 passage
• Pharmacists' interventions on clinical asthma outcomes: a systematic review.1 passage
• Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis.1 passage
• Pharmacological treatment optimisation for stable COPD: an endless story? Proposals from the Société de Pneumologie de Langue Française.1 passage
• Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI.1 passage
• Pharyngeal collapsibility during sleep is elevated in insulin-resistant females with morbid obesity.1 passage
• Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.1 passage
• Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.1 passage
• Phenotype and outcome of pulmonary arterial hypertension patients carrying a1 passage
• Phenotype characterisation of1 passage
• Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity.1 passage
• Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.1 passage
• Phenotypes of organ involvement in sarcoidosis.1 passage
• Phenotypes of symptomatic airways disease in China and New Zealand.1 passage
• Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease.1 passage
• Physical activity and exercise capacity in patients with moderate COPD exacerbations.1 passage
• Physical activity as a moderator for obstructive sleep apnoea and cardiometabolic risk in the EPISONO study.1 passage
• Physical activity is not associated with spirometric indices in lung-healthy German youth.1 passage
• Physical activity, sedentary behavior, and incidence of obstructive sleep apnea in three prospective US cohorts.1 passage
• Physiological and clinical relevance of exercise ventilatory efficiency in COPD.1 passage
• Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.1 passage
• Pilot randomised trial of a healthy eating behavioural intervention in uncontrolled asthma.1 passage
• Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.1 passage
• Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.1 passage
• Plasma metabolomics exhibit response to therapy in chronic thromboembolic pulmonary hypertension.1 passage
• Plasma mitochondrial DNA is associated with extrapulmonary sarcoidosis.1 passage
• Plasma pro-surfactant protein B and lung function decline in smokers.1 passage
• Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation.1 passage
• Pleural irrigation trial (PIT): a randomised controlled trial of pleural irrigation with normal saline versus standard care in patients with pleural infection.1 passage
• Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact.1 passage
• Pneumonia1 passage
• Point-of-care lung ultrasound assessment for risk stratification and therapy guiding in COVID-19 patients: a prospective noninterventional study.1 passage
• Polymorphisms in cancer-related pathway genes and lung cancer.1 passage
• Population-based case-finding to identify subjects with undiagnosed asthma or COPD.1 passage
• Positron emission tomography in the diagnostic work-up of screening-detected lung nodules.1 passage
• Post-approval upper airway stimulation predictors of treatment effectiveness in the ADHERE registry.1 passage
• Potassium channels in pulmonary arterial hypertension.1 passage
• Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.1 passage
• Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond.1 passage
• Potential therapeutic targets for lung repair during human1 passage
• Pre-eclampsia and childhood asthma.1 passage
• Precision medicine in airway diseases: moving to clinical practice.1 passage
• Preclinical validation and imaging of Wnt-induced repair in human 3D lung tissue cultures.1 passage
• Predicting EGFR mutation status in lung adenocarcinoma on computed tomography image using deep learning.1 passage
• Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review.1 passage
• Predicting epiglottic collapse in patients with obstructive sleep apnoea.1 passage
• Predicting extubation outcomes using the Heart Rate Characteristics index in preterm infants: a cohort study.1 passage
• Predicting mortality in bronchiectasis using bronchiectasis severity index and FACED scores: a 19-year cohort study.1 passage
• Predicting outcomes in rheumatoid arthritis related interstitial lung disease.1 passage
• Predicting response to oxygen therapy in obstructive sleep apnoea patients using a 10-minute daytime test.1 passage
• Predicting risk of undiagnosed COPD: development and validation of the TargetCOPD score.1 passage
• Predicting the risk of respiratory distress in newborns with congenital pulmonary malformations.1 passage
• Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.1 passage
• Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.1 passage
• Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study.1 passage
• Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia.1 passage
• Predictive value of exhaled nitric oxide in the management of asthma: a systematic review.1 passage
• Predictors of accelerated decline in lung function in adult-onset asthma.1 passage
• Predictors of costs from the hospital perspective of primary pulmonary embolism.1 passage
• Predictors of delirium after cardiac surgery in patients with sleep disordered breathing.1 passage
• Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study.1 passage
• Predictors of mortality in chronic pulmonary aspergillosis.1 passage
• Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.1 passage
• Predictors of objective cough frequency in pulmonary sarcoidosis.1 passage
• Predictors of obstructive sleep apnoea in patients admitted for acute coronary syndrome.1 passage
• Predictors of pneumonia in lower respiratory tract infections: 3C prospective cough complication cohort study.1 passage
• Predictors of progression in systemic sclerosis patients with interstitial lung disease.1 passage
• Predictors of severe asthma attack re-attendance in Ecuadorian children: a cohort study.1 passage
• Predictors of sleepiness in obstructive sleep apnoea at baseline and after 6 months of continuous positive airway pressure therapy.1 passage
• Preliminary validation of the NTM Module: a patient-reported outcome measure for patients with pulmonary nontuberculous mycobacterial disease.1 passage
• Prenatal and prepubertal exposures to tobacco smoke in men may cause lower lung function in future offspring: a three-generation study using a causal modelling approach.1 passage
• Prenatal antibiotic exposure and childhood asthma: a population-based study.1 passage
• Prenatal exposure to antibiotics and wheezing in infancy: a birth cohort study.1 passage
• Prenatal maternal psychological stress and childhood asthma and wheezing: a meta-analysis.1 passage
• Prenatal tobacco exposure and risk of asthma and allergy outcomes in childhood.1 passage
• Prescribed analgesics in pregnancy and risk of childhood asthma.1 passage
• Present and future utility of computed tomography scanning in the assessment and management of COPD.1 passage
• Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study.1 passage
• Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis.1 passage
• Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.1 passage
• Prevalence and risk factors for COPD in farmers: a cross-sectional controlled study.1 passage
• Prevalence of and treatment outcomes for patients with obstructive sleep apnoea identified by preoperative screening compared with clinician referrals.1 passage
• Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.1 passage
• Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR).1 passage
• Prevalence, progression and impact of chronic cough on employment in Northern Europe.1 passage
• Prevalence, risk factors and clinical correlates of COPD in a rural setting in Tanzania.1 passage
• Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: a population survey.1 passage
• Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.1 passage
• Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling.1 passage
• Primary ciliary dyskinesia ciliated airway cells show increased susceptibility to1 passage
• Primary ciliary dyskinesia with normal ultrastructure: three-dimensional tomography detects absence of DNAH11.1 passage
• Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data.1 passage
• Principles of practice parameters for the treatment of sleep disordered breathing in the elderly and frail elderly: the consensus of the International Geriatric Sleep Medicine Task Force.1 passage
• Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?1 passage
• Procedure volume and mortality after surgical lung biopsy in interstitial lung disease.1 passage
• Profibrotic function of pulmonary group 2 innate lymphoid cells is controlled by regnase-1.1 passage
• Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension.1 passage
• Profiling of healthy and asthmatic airway smooth muscle cells following interleukin-1β treatment: a novel role for CCL20 in chronic mucus hypersecretion.1 passage
• Profiling of lung SARS-CoV-2 and influenza virus infection dissects virus-specific host responses and gene signatures.1 passage
• Prognostic assessment in COPD without lung function: the B-AE-D indices.1 passage
• Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study.1 passage
• Prognostic factors for adverse outcomes in patients with COVID-19: a field-wide systematic review and meta-analysis.1 passage
• Prognostic factors for development of acute respiratory distress syndrome following traumatic injury - a systematic review and meta-analysis.1 passage
• Prognostic factors of severe community-acquired staphylococcal pneumonia in France.1 passage
• Prognostic impact of copeptin in pulmonary embolism: a multicentre validation study.1 passage
• Prognostic phenotypes of early-stage lung adenocarcinoma.1 passage
• Prognostic significance of chronic respiratory symptoms in individuals with normal spirometry.1 passage
• Prognostic value of cardiovascular parameters in computed tomography pulmonary angiography in patients with acute pulmonary embolism.1 passage
• Prognostic value of right ventricular dilatation in patients with low-risk pulmonary embolism.1 passage
• Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension.1 passage
• Program of Integrated Care for Patients with Chronic Obstructive Pulmonary Disease and Multiple Comorbidities (PIC COPD1 passage
• Progression to tuberculosis disease increases with multiple exposures.1 passage
• Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).1 passage
• Progressive ventilation inhomogeneity in infants with cystic fibrosis after pulmonary infection.1 passage
• Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis.1 passage
• Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma.1 passage
• Prospective study of insomnia and incident asthma in adults: the HUNT study.1 passage
• Prospective validation of right ventricular role in primary graft dysfunction after lung transplantation.1 passage
• Prospective validation of the RAPID clinical risk prediction score in adult patients with pleural infection: the PILOT study.1 passage
• Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events.1 passage
• Protean proteases: at the cutting edge of lung diseases.1 passage
• Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis.1 passage
• Protective efficacy of 6-week regimen for latent tuberculosis infection treatment in rural China: 5-year follow-up of a randomised controlled trial.1 passage
• Protective role for club cell secretory protein-16 (CC16) in the development of COPD.1 passage
• Proteomic profile of cystic fibrosis sputum cells in adults chronically infected with1 passage
• Pseudomonas aeruginosa quorum sensing molecules correlate with clinical status in cystic fibrosis.1 passage
• Pseudomonas infection and mucociliary and absorptive clearance in the cystic fibrosis lung.1 passage
• Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis.1 passage
• Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.1 passage
• Pulmonary arterial hypertension associated with primary Sjögren's syndrome: a multicentre cohort study from China.1 passage
• Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study.1 passage
• Pulmonary arterial hypertension with below threshold pulmonary vascular resistance.1 passage
• Pulmonary arterial pressure at rest and during exercise in chronic mountain sickness: a meta-analysis.1 passage
• Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis.1 passage
• Pulmonary artery to aorta ratio and risk of all-cause mortality in the general population: the Rotterdam Study.1 passage
• Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.1 passage
• Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research.1 passage
• Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung study.1 passage
• Pulmonary function deficits in newborn screened infants with cystic fibrosis managed with standard UK care are mild and transient.1 passage
• Pulmonary haemodynamics during recovery from maximum incremental cycling exercise.1 passage
• Pulmonary hypertension after bone marrow transplantation in children.1 passage
• Pulmonary hypertension due to left heart disease.1 passage
• Pulmonary hypertension in chronic lung disease and hypoxia.1 passage
• Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.1 passage
• Pulmonary manifestations in adult patients with chronic granulomatous disease.1 passage
• Pulmonary mucosa-associated lymphoid tissue lymphoma revisited.1 passage
• Pulmonary rehabilitation in bronchiectasis: a propensity-matched study.1 passage
• Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial.1 passage
• Pulmonary type-2 innate lymphoid cells in paediatric severe asthma: phenotype and response to steroids.1 passage
• Pulmonary vascular density: comparison of findings on computed tomography imaging with histology.1 passage
• Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases: Highlights from basic research to therapy.1 passage
• Pulmonary vascular resistance and compliance relationship in pulmonary hypertension.1 passage
• Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.1 passage
• Pulmonary vascular response patterns during exercise in interstitial lung disease.1 passage
• Pulmonary veno-occlusive disease.1 passage
• Quality of life in patients with chronic thromboembolic pulmonary hypertension.1 passage
• Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.1 passage
• Quantifying comorbidity in individuals with COPD: a population study.1 passage
• Quantifying the magnitude of pharyngeal obstruction during sleep using airflow shape.1 passage
• Quantifying the ventilatory control contribution to sleep apnoea using polysomnography.1 passage
• Quantitative analysis of airway obstruction in lymphangioleiomyomatosis.1 passage
• Quantitative high-resolution computed tomography fibrosis score: performance characteristics in idiopathic pulmonary fibrosis.1 passage
• Quantitative multivolume proton-magnetic resonance imaging in patients with cystic fibrosis lung disease: comparison with clinical indicators.1 passage
• R-Scale for Pulmonary Fibrosis (PF): a simple, visual tool for the assessment of health-related quality of life.1 passage
• REM-associated sleep apnoea: prevalence and clinical significance in the HypnoLaus cohort.1 passage
• RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.1 passage
• RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.1 passage
• RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors.1 passage
• RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation.1 passage
• Radial endobronchial ultrasound images for ground-glass opacity pulmonary lesions.1 passage
• Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS.1 passage
• Radiographic pulmonary vessel volume, lung function and airways disease in the Framingham Heart Study.1 passage
• Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia.1 passage
• Radiomic measures from chest high-resolution computed tomography associated with lung function in sarcoidosis.1 passage
• Randomised comparison of needle aspiration and chest tube drainage in spontaneous pneumothorax.1 passage
• Randomised controlled trial of a prognostic assessment and management pathway to reduce the length of hospital stay in normotensive patients with acute pulmonary embolism.1 passage
• Randomised controlled trial of polysomnographic titration of noninvasive ventilation.1 passage
• Randomised controlled trials in severe asthma: selection by phenotype or stereotype.1 passage
• Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension.1 passage
• Randomised trial of the P2X1 passage
• Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.1 passage
• Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19.1 passage
• Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells.1 passage
• Rates of change in FEV1 passage
• Re-imagining cystic fibrosis care: next generation thinking.1 passage
• Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?1 passage
• Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials.1 passage
• Real-life assessment of the multidimensional nature of dyspnoea in COPD outpatients.1 passage
• Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.1 passage
• Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.1 passage
• Recommendations for respiratory syncytial virus surveillance at the national level.1 passage
• Recurrence rates in primary spontaneous pneumothorax: a systematic review and meta-analysis.1 passage
• Recurrent NRAS mutations in pulmonary Langerhans cell histiocytosis.1 passage
• Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma.1 passage
• Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.1 passage
• Reduction in1 passage
• Reductions in dead space ventilation with nasal high flow depend on physiological dead space volume: metabolic hood measurements during sleep in patients with COPD and controls.1 passage
• Reference equations for pulmonary diffusing capacity of carbon monoxide and nitric oxide in adult Caucasians.1 passage
• Referral criteria to palliative care for patients with respiratory disease: a systematic review.1 passage
• Regulator of telomere length 1 (1 passage
• Relationship between glucosamine use and the risk of lung cancer: data from a nationwide prospective cohort study.1 passage
• Relationship of obstructive sleep apnoea severity and subclinical systemic atherosclerosis.1 passage
• Relative and absolute lung function change in a general population aged 60-102 years.1 passage
• Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.1 passage
• Report of the European Respiratory Society/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis.1 passage
• Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer.1 passage
• Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator.1 passage
• Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration.1 passage
• Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases.1 passage
• Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis.1 passage
• Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).1 passage
• Respiratory muscle imaging by ultrasound and MRI in neuromuscular disorders.1 passage
• Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?1 passage
• Resting pulmonary artery pressure of 21-24 mmHg predicts abnormal exercise haemodynamics.1 passage
• Right atrial function is associated with RV diastolic stiffness: RA-RV interaction in pulmonary arterial hypertension.1 passage
• Right heart thrombi in pulmonary embolism.1 passage
• Right ventricular dyssynchrony and exercise capacity in idiopathic pulmonary arterial hypertension.1 passage
• Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).1 passage
• Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2).1 passage
• Riociguat for treatment of pulmonary hypertension in COPD: a translational study.1 passage
• Risk assessment in medically treated chronic thromboembolic pulmonary hypertension patients.1 passage
• Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.1 passage
• Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.1 passage
• Risk factors associated with the development of interstitial lung abnormalities.1 passage
• Risk factors for admission to hospital with laboratory-confirmed influenza in young children: birth cohort study.1 passage
• Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study.1 passage
• Risk factors for lung cancer worldwide.1 passage
• Risk factors for lung disease progression in children with cystic fibrosis.1 passage
• Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.1 passage
• Risk factors for short-term outcomes after thoracoscopic lobectomy for lung cancer.1 passage
• Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity.1 passage
• Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).1 passage
• Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976-2013.1 passage
• Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit.1 passage
• Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.1 passage
• Risk of first and recurrent serious infection in sarcoidosis: a Swedish register-based cohort study.1 passage
• Risk of hypersensitivity pneumonitis and interstitial lung diseases among pigeon breeders.1 passage
• Risk of pulmonary embolism and deep venous thrombosis in patients with asthma: a nationwide case-control study from Sweden.1 passage
• Risk of recurrent venous thromboembolism in COPD patients: results from a prospective cohort study.1 passage
• Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.1 passage
• Risk stratification and medical therapy of pulmonary arterial hypertension.1 passage
• Risk stratification in pulmonary arterial hypertension using Bayesian analysis.1 passage
• Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin.1 passage
• Risks for cold frequency vary by sex: role of asthma, age, TLR7 and leukocyte subsets.1 passage
• Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.1 passage
• Role of angiopoietin-2 in venous thrombus resolution and chronic thromboembolic disease.1 passage
• Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.1 passage
• Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem.1 passage
• Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension.1 passage
• SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.1 passage
• SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772).1 passage
• SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis.1 passage
• SPLUNC1 degradation by the cystic fibrosis mucosal environment drives airway surface liquid dehydration.1 passage
• SPLUNC1: a novel marker of cystic fibrosis exacerbations.1 passage
• Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis.1 passage
• Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study.1 passage
• Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.1 passage
• Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden.1 passage
• Sarcoidosis mortality in Sweden: a population-based cohort study.1 passage
• Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis.1 passage
• Scan-based competing death risk model for reevaluating lung cancer computed tomography screening eligibility.1 passage
• Screening and treatment of tuberculosis among pregnant women in Stockholm, Sweden, 2016-2017.1 passage
• Screening for pulmonary arterial hypertension in adults carrying a1 passage
• Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort.1 passage
• Screening for tuberculosis in migrants and visitors from high-incidence settings: present and future perspectives.1 passage
• Selection criteria for intensive care unit referral of lung cancer patients: a pilot study.1 passage
• Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.1 passage
• Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.1 passage
• Self-titration of inhaled corticosteroid and β1 passage
• Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis1 passage
• Sensitisation to staphylococcal enterotoxins and asthma severity: a longitudinal study in the EGEA cohort.1 passage
• Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.1 passage
• Sequential multimodality bronchoscopic investigation of peripheral pulmonary lesions.1 passage
• Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group.1 passage
• Serodiagnosis of Mycobacterium abscessus complex infection in cystic fibrosis.1 passage
• Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset.1 passage
• Serotonergic antidepressant use and morbidity and mortality among older adults with COPD.1 passage
• Serotype transmission dynamics and reduced incidence of invasive pneumococcal disease caused by different serotypes after implementation of non-pharmaceutical interventions during COVID-19 pandemic.1 passage
• Sertraline in symptomatic chronic breathlessness: a double blind, randomised trial.1 passage
• Serum 25-hydroxyvitamin D level, smoking and lung function in adults: the HUNT Study.1 passage
• Serum 25-hydroxyvitamin D levels and lung function in adults with asthma: the HUNT Study.1 passage
• Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study.1 passage
• Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis.1 passage
• Serum and pulmonary uric acid in pulmonary arterial hypertension.1 passage
• Serum levels of hyaluronic acid are associated with COPD severity and predict survival.1 passage
• Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis.1 passage
• Serum periostin in obstructive airways disease.1 passage
• Severe asthma exists despite suppressed tissue inflammation: findings of the U-BIOPRED study.1 passage
• Severe desaturations increase psychomotor vigilance task-based median reaction time and number of lapses in obstructive sleep apnoea patients.1 passage
• Severe haemoptysis in patients with nonsmall cell lung carcinoma.1 passage
• Severe pulmonary hypertension in lung disease: phenotypes and response to treatment.1 passage
• Severity and outcome of cystic lung disease in women with tuberous sclerosis complex.1 passage
• Sex differences in the associations of obstructive sleep apnoea with epidemiological factors.1 passage
• Sex-specific features of emphysema among current and former smokers with COPD.1 passage
• Sex-specific impact of asthma during pregnancy on infant gut microbiota.1 passage
• Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis.1 passage
• Shared genetics of asthma and mental health disorders: a large-scale genome-wide cross-trait analysis.1 passage
• Short-acting β1 passage
• Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth.1 passage
• Short-course regimens of rifapentine plus isoniazid to treat latent tuberculosis infection in older Chinese patients: a randomised controlled study.1 passage
• Short-term and long-term effect of a high-intensity pulmonary rehabilitation programme in obese patients with asthma: a randomised controlled trial.1 passage
• Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor?1 passage
• Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?1 passage
• Should we worry about bedaquiline exposure in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis?1 passage
• Similar distribution of peripheral blood eosinophil counts in European and East Asian populations from investigations of large-scale general population studies: the Nagahama Study.1 passage
• Simulator training for endobronchial ultrasound: a randomised controlled trial.1 passage
• Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function1 passage
• Sleep apnoea and the hypothalamic-pituitary-adrenal axis in men and women: effects of continuous positive airway pressure.1 passage
• Sleep apnoea in the asymptomatic elderly: a real issue for the brain?1 passage
• Sleep apnoea in the elderly: a great challenge for the future.1 passage
• Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA).1 passage
• Sleep disordered breathing and enlargement of the right heart after myocardial infarction.1 passage
• Sleep disordered breathing and metabolic comorbidities across sex and menopausal status in East Asians: the Nagahama Study.1 passage
• Sleep laboratories reopening and COVID-19: a European perspective.1 passage
• Sleep-related breathing disorders and pulmonary hypertension.1 passage
• Sleeping on animal fur is related to asthma outcomes in later childhood.1 passage
• Small airways dysfunction: the link between allergic rhinitis and allergic asthma.1 passage
• Small cell lung cancer in never-smokers.1 passage
• Smoke-free legislation and childhood hospitalisations for respiratory tract infections.1 passage
• Smoking adversely affects treatment response, outcome and relapse in tuberculosis.1 passage
• Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension.1 passage
• Social inequalities in wheezing in children: findings from the UK Millennium Cohort Study.1 passage
• Socioeconomic biases in asthma control and specialist referral of possible severe asthma.1 passage
• Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.1 passage
• Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies.1 passage
• Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.1 passage
• Spermine promotes pulmonary vascular remodelling and its synthase is a therapeutic target for pulmonary arterial hypertension.1 passage
• Spirometric reference values for Malagasy adults aged 18-73 years.1 passage
• Sputum mast cell subtypes relate to eosinophilia and corticosteroid response in asthma.1 passage
• Sputum neutrophil elastase associates with microbiota and1 passage
• Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis.1 passage
• Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.1 passage
• Staging of lung cancer: the role of noninvasive, minimally invasive and invasive techniques.1 passage
• Standardisation and application of the single-breath determination of nitric oxide uptake in the lung.1 passage
• Standardised shorter regimens1 passage
• Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit.1 passage
• Statins as adjunct therapy in COPD: is it time to target innate immunity and cardiovascular risk?1 passage
• Stopping1 passage
• Stratifying infants with cystic fibrosis for disease severity using intestinal organoid swelling as a biomarker of CFTR function.1 passage
• Structural brain correlates of obstructive sleep apnoea in older adults at risk for dementia.1 passage
• Structural determinants of long-term functional outcomes in young children with cystic fibrosis.1 passage
• Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.1 passage
• Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.1 passage
• Successful1 passage
• Suitable reference genes determination for real-time PCR using induced sputum samples.1 passage
• Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation.1 passage
• Surgery or radiotherapy for stage I lung cancer? An intention-to-treat analysis.1 passage
• Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997-2008.1 passage
• Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.1 passage
• Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.1 passage
• Survival and quality of life after early discharge in low-risk pulmonary embolism.1 passage
• Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.1 passage
• Survival in individuals with severe alpha 1-antitrypsin deficiency (PiZZ) in comparison to a general population with known smoking habits.1 passage
• Synergistic role of HSP90α and HSP90β to promote myofibroblast persistence in lung fibrosis.1 passage
• Systematic and combined endosonographic staging of lung cancer (SCORE study).1 passage
• Systematic evaluation and external validation of 22 prognostic models among hospitalised adults with COVID-19: an observational cohort study.1 passage
• Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer.1 passage
• Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design.1 passage
• Systems biology and big data in asthma and allergy: recent discoveries and emerging challenges.1 passage
• T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis.1 passage
• T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED.1 passage
• TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications.1 passage
• TLR2-mediated innate immune priming boosts lung anti-viral immunity.1 passage
• TLR7/8 regulates type I and type III interferon signalling in rhinovirus 1b-induced allergic asthma.1 passage
• TRIM33 prevents pulmonary fibrosis by impairing TGF-β1 signalling.1 passage
• TRPA1 activation in a human sensory neuronal model: relevance to cough hypersensitivity?1 passage
• Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis.1 passage
• Targeted proteomics of right heart adaptation to pulmonary arterial hypertension.1 passage
• Targeting HIF2α-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension.1 passage
• Targeting TMEM16A to reverse vasoconstriction and remodelling in idiopathic pulmonary arterial hypertension.1 passage
• Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages.1 passage
• Targeting fatty acid amide hydrolase as a therapeutic strategy for antitussive therapy.1 passage
• Targeting transforming growth factor-β receptors in pulmonary hypertension.1 passage
• Targeting treatable traits in severe asthma: a randomised controlled trial.1 passage
• Technical standards for respiratory oscillometry.1 passage
• Tele-monitoring of ventilator-dependent patients: a European Respiratory Society Statement.1 passage
• Telomere length and genetic variant associations with interstitial lung disease progression and survival.1 passage
• Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive.1 passage
• Temporal airway microbiome changes related to ventilator-associated pneumonia in children.1 passage
• Temporal stability of multitrigger and episodic viral wheeze in early childhood.1 passage
• Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry.1 passage
• Tests for tuberculosis infection: landscape analysis.1 passage
• Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome?1 passage
• Th17 cytokines: novel potential therapeutic targets for COPD pathogenesis and exacerbations.1 passage
• The2 passages
• The "one airway, one disease" concept in light of Th2 inflammation.1 passage
• The ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertension.1 passage
• The DNA repair transcriptome in severe COPD.1 passage
• The ERS Research Agency: the beginning.1 passage
• The Effect of Pain Conditioning on Experimentally Evoked Cough: Evidence of Impaired Endogenous Inhibitory Control Mechanisms in Refractory Chronic Cough.1 passage
• The Electronic Asthma Management System (eAMS) improves primary care asthma management.1 passage
• The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors.1 passage
• The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation.1 passage
• The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.1 passage
• The PELICAN (Prematurity's Effect on the Lungs In Children and Adults Network) ERS Clinical Research Collaboration: understanding the impact of preterm birth on lung health throughout life.1 passage
• The PROactive instruments to measure physical activity in patients with chronic obstructive pulmonary disease.1 passage
• The Pleural Effusion And Symptom Evaluation (PLEASE) study of breathlessness in patients with a symptomatic pleural effusion.1 passage
• The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19.1 passage
• The Severe Heterogeneous Asthma Research collaboration, Patient-centred (SHARP) ERS Clinical Research Collaboration: a new dawn in asthma research.1 passage
• The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS Clinical Research Collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers.1 passage
• The accuracy of forced vital capacity for diagnosing restrictive allograft syndrome and mixed phenotype of chronic lung allograft dysfunction.1 passage
• The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study.1 passage
• The asbestos fibre burden in human lungs: new insights into the chrysotile debate.1 passage
• The assessment of short and long term changes in lung function in CF using1 passage
• The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy.1 passage
• The association between chronic airflow obstruction and poverty in 12 sites of the multinational BOLD study.1 passage
• The associations of interstitial lung abnormalities with cancer diagnoses and mortality.1 passage
• The benefits of a systematic assessment of respiratory health in illness-susceptible athletes.1 passage
• The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts.1 passage
• The changing face of a rare disease: lymphangioleiomyomatosis.1 passage
• The clinical significance of oropharyngeal cultures in young children with cystic fibrosis.1 passage
• The coexistence of asthma and COPD: risk factors, clinical history and lung function trajectories.1 passage
• The construction and validation of the Severe Asthma Questionnaire.1 passage
• The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.1 passage
• The cumulative effect of inflammation and infection on structural lung disease in early cystic fibrosis.1 passage
• The development and validation of the Bronchiectasis Health Questionnaire.1 passage
• The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model.1 passage
• The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial.1 passage
• The economic effects of supporting tuberculosis-affected households in Peru.1 passage
• The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function.1 passage
• The effect of anti-acid therapy on survival in idiopathic pulmonary fibrosis: a methodological review of observational studies.1 passage
• The effect of breastfeeding on lung function at 12 and 18 years: a prospective cohort study.1 passage
• The effect of exacerbation history on outcomes in the IMPACT trial.1 passage
• The effect of fluid overload on sleep apnoea severity in haemodialysis patients.1 passage
• The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.1 passage
• The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection.1 passage
• The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial.1 passage
• The effect of sex and age on the comorbidity burden of OSA: an observational analysis from a large nationwide US health claims database.1 passage
• The effect of smoking on lung function: a clinical study of adult-onset asthma.1 passage
• The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.1 passage
• The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM).1 passage
• The effect of treatment for sleep apnoea on determinants of blood pressure control.1 passage
• The effectiveness of contact investigation among contacts of tuberculosis patients: a systematic review and meta-analysis.1 passage
• The effects of marijuana smoking on lung function in older people.1 passage
• The emerging role of epigenetics in pulmonary hypertension.1 passage
• The emerging role of mast cell proteases in asthma.1 passage
• The emerging role of myeloid-derived suppressor cells in lung diseases.1 passage
• The emerging role of transient receptor potential channels in chronic lung disease.1 passage
• The genetic basis of idiopathic pulmonary fibrosis.1 passage
• The global prevalence of latent tuberculosis: a systematic review and meta-analysis.1 passage
• The impact of COVID-19 on patients with asthma.1 passage
• The impact of acute air pollution fluctuations on bronchiectasis pulmonary exacerbation: a case-crossover analysis.1 passage
• The impact of digital health technologies on tuberculosis treatment: a systematic review.1 passage
• The impact of obstructive sleep apnoea on the aorta.1 passage
• The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension.1 passage
• The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada.1 passage
• The importance of interventional timing in the bleomycin model of pulmonary fibrosis.1 passage
• The importance of patient perspectives in pulmonary hypertension.1 passage
• The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group: Endorsed by the International Primary Care Respiratory Group and the World Allergy Organization.1 passage
• The incidence of tuberculosis among adolescents and young adults: a global estimate.1 passage
• The independent contribution of1 passage
• The independent role of prenatal and postnatal exposure to active and passive smoking on the development of early wheeze in children.1 passage
• The inflammatory cell landscape in the lungs of patients with idiopathic pulmonary arterial hypertension.1 passage
• The innate immune function of airway epithelial cells in inflammatory lung disease.1 passage
• The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease.1 passage
• The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results.1 passage
• The interrelatedness of chronic cough and chronic pain.1 passage
• The lived experience with idiopathic pulmonary fibrosis: a qualitative study.1 passage
• The lung cancer patient, the pneumologist and palliative care: a developing alliance.1 passage
• The management of mild asthma.1 passage
• The microbiology of pleural infection in adults: a systematic review.1 passage
• The microbiome in respiratory medicine: current challenges and future perspectives.1 passage
• The minimal important difference for the St George's Respiratory Questionnaire in patients with severe COPD.1 passage
• The mode of action of anticholinergics in asthma.1 passage
• The molecular and cellular mechanisms associated with the destruction of terminal bronchioles in chronic obstructive pulmonary disease.1 passage
• The mucus bundles responsible for airway cleaning are retained in cystic fibrosis and by cholinergic stimulation.1 passage
• The natural history of progressive fibrosing interstitial lung diseases.1 passage
• The novel bronchodilator navafenterol: a phase 2a, multi-centre, randomised, double-blind, placebo-controlled crossover trial in COPD.1 passage
• The occupations at increased risk of COPD: analysis of lifetime job-histories in the population-based UK Biobank Cohort.1 passage
• The optimisation of noninvasive ventilation in amyotrophic lateral sclerosis: a systematic review.1 passage
• The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions.1 passage
• The paradoxes of asthma management: time for a new approach?1 passage
• The pathophysiological role of novel pulmonary arterial hypertension gene1 passage
• The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD.1 passage
• The physiologic basis of pulmonary arterial hypertension.1 passage
• The physiological basis of pulmonary gas exchange: implications for clinical interpretation of arterial blood gases.1 passage
• The prevalence of diagnosed α1-antitrypsin deficiency and its comorbidities: results from a large population-based database.1 passage
• The psychometric properties of the King's Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases.1 passage
• The relationship between asthma and suicidal behaviours: a systematic literature review.1 passage
• The relationship between body fat and respiratory function in young adults.1 passage
• The reproducibility and responsiveness of the lung clearance index in bronchiectasis.1 passage
• The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor.1 passage
• The risk of community-acquired pneumonia in children using gastric acid suppressants.1 passage
• The risk of multidrug- or rifampicin-resistance in males1 passage
• The risk of mycobacterial infections associated with inhaled corticosteroid use.1 passage
• The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial.1 passage
• The role of air pollution and lung function in cognitive impairment.1 passage
• The role of the 17q21 genotype in the prevention of early childhood asthma and recurrent wheeze by vitamin D.1 passage
• The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis.1 passage
• The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.1 passage
• The self-fulfilling prophecy of pulmonary fibrosis: a selective inspection of pathological signalling loops.1 passage
• The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD.1 passage
• The striated muscles in pulmonary arterial hypertension: adaptations beyond the right ventricle.1 passage
• The undiagnosed disease burden associated with alpha-1 antitrypsin deficiency genotypes.1 passage
• The use of whole-genome sequencing in cluster investigation of a multidrug-resistant tuberculosis outbreak.1 passage
• The utility and safety of linear endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in the paediatric population.1 passage
• The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis.1 passage
• Therapeutic management of ALK+ nonsmall cell lung cancer patients.1 passage
• Theratyping cystic fibrosis1 passage
• Thoracic dust exposure is associated with lung function decline in cement production workers.1 passage
• Tidal flow variability measured by impedance pneumography relates to childhood asthma risk.1 passage
• Time trends in surgery for lung cancer in France from 2005 to 2012: a nationwide study.1 passage
• Time-course of upper respiratory tract viral infection and COPD exacerbation.1 passage
• Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.1 passage
• Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4).1 passage
• Tiotropium treatment for bronchiectasis: a randomised, placebo-controlled, crossover trial.1 passage
• Tobacco and tuberculosis: could we improve tuberculosis outcomes by helping patients to stop smoking?1 passage
• Tobacco smoke exposure in early life and adolescence in relation to lung function.1 passage
• Topological data analysis reveals genotype-phenotype relationships in primary ciliary dyskinesia.1 passage
• Towards a close computed tomography monitoring approach for screen detected subsolid pulmonary nodules?1 passage
• Towards an expert consensus to delineate a clinical syndrome of chronic breathlessness.1 passage
• Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data.1 passage
• Towards the standardisation of lung sound nomenclature.1 passage
• Towards tuberculosis elimination: an action framework for low-incidence countries.1 passage
• Tracheal replacement.1 passage
• Traffic exposures, air pollution and outcomes in pulmonary arterial hypertension: a UK cohort study analysis.1 passage
• Traffic-related air pollution and alveolar nitric oxide in southern California children.1 passage
• Traffic-related air pollution exposure over a 5-year period is associated with increased risk of asthma and poor lung function in middle age.1 passage
• Trajectory and mortality of preserved ratio impaired spirometry: the Rotterdam Study.1 passage
• Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma.1 passage
• Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial.1 passage
• Transbronchial mediastinal cryobiopsy in the diagnosis of mediastinal lesions: a randomised trial.1 passage
• Transbronchial needle aspiration in peripheral pulmonary lesions: a systematic review and meta-analysis.1 passage
• Transcription factors and miRNAs that regulate fetal to adult CFTR expression change are new targets for cystic fibrosis.1 passage
• Transcriptional characterisation of human lung cells identifies novel mesenchymal lineage markers.1 passage
• Transcriptome profiling reveals the complexity of pirfenidone effects in idiopathic pulmonary fibrosis.1 passage
• Transcriptomic analysis of CFTR-impaired endothelial cells reveals a pro-inflammatory phenotype.1 passage
• Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma.1 passage
• Transcriptomic investigation reveals donor-specific gene signatures in human lung transplants.1 passage
• Transcriptomics of atopy and atopic asthma in white blood cells from children and adolescents.1 passage
• Transcriptomics of bronchoalveolar lavage cells identifies new molecular endotypes of sarcoidosis.1 passage
• Transfer factor, lung volumes, resistance and ventilation distribution in healthy adults.1 passage
• Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution.1 passage
• Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.1 passage
• Treatable traits: toward precision medicine of chronic airway diseases.1 passage
• Treating breathlessness1 passage
• Treatment of limited disease small cell lung cancer: the multidisciplinary team.1 passage
• Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.1 passage
• Treatment options in type-2 low asthma.1 passage
• Treatment outcomes of obstructive sleep apnoea in obese community-dwelling children: the NANOS study.1 passage
• Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs.1 passage
• Trends and predictors of asthma costs: results from a 10-year longitudinal study.1 passage
• Trends in mediastinal nodal staging and its impact on unforeseen N2 and survival in lung cancer.1 passage
• Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001-2013.1 passage
• Trends in risk stratification, in-hospital management and mortality of patients with acute pulmonary embolism: an analysis from the China pUlmonary thromboembolism REgistry Study (CURES).1 passage
• Trends in worldwide asthma prevalence.1 passage
• Trends of testing for and diagnosis of α1 passage
• Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.1 passage
• Triple therapy1 passage
• Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies.1 passage
• Tropism and innate host responses of influenza A/H5N6 virus: an analysis of1 passage
• Tropism of influenza B viruses in human respiratory tract explants and airway organoids.1 passage
• Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions.1 passage
• Tuberculosis and COVID-19 co-infection: description of the global cohort.1 passage
• Tuberculosis associates with both airflow obstruction and low lung function: BOLD results.1 passage
• Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices.1 passage
• Tuberculosis diagnostic accuracy of stool Xpert MTB/RIF and urine AlereLAM in vulnerable children.1 passage
• Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes.1 passage
• Tuberculosis prevention in children: a prospective community-based study in South Africa.1 passage
• Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer.1 passage
• Tussive challenge with ATP and AMP: does it reveal cough hypersensitivity?1 passage
• Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease.1 passage
• Tyk2 as a target for immune regulation in human viral/bacterial pneumonia.1 passage
• Ultrasound elastography: a novel tool for the differential diagnosis of pleural effusion.1 passage
• Uncovering the mechanisms of exertional dyspnoea in combined pulmonary fibrosis and emphysema.1 passage
• Understanding asthma-specific quality of life: moving beyond asthma symptoms and severity.1 passage
• Understanding patients' perceptions of asthma control: a qualitative study.1 passage
• Understanding the impact of the lung microenvironment to enhance the therapeutic potential of mesenchymal stromal cells for acute respiratory distress syndrome.1 passage
• Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation.1 passage
• Understanding the pathophysiological mechanisms of cardiometabolic complications in obstructive sleep apnoea: towards personalised treatment approaches.1 passage
• Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review.1 passage
• Unemployment in chronic airflow obstruction around the world: results from the BOLD study.1 passage
• Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.1 passage
• Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis.1 passage
• Unmasking the hidden tuberculosis mortality burden in a large1 passage
• Unravelling the complexity of COPD by microRNAs: it's a small world after all.1 passage
• Unsupervised phenotypic clustering for determining clinical status in children with cystic fibrosis.1 passage
• Upfront combination therapy reduces right ventricular volumes in pulmonary arterial hypertension.1 passage
• Upfront triple combination therapy in severe paediatric pulmonary arterial hypertension.1 passage
• Upper airway and systemic inflammation in obstructive sleep apnoea.1 passage
• Urban green and grey space in relation to respiratory health in children.1 passage
• Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the First European Congress on Adherence to Therapy.1 passage
• Urinary metabotype of severe asthma evidences decreased carnitine metabolism independent of oral corticosteroid treatment in the U-BIOPRED study.1 passage
• Use of Singing for Lung Health as an alternative training modality within pulmonary rehabilitation for COPD: an RCT.1 passage
• Use of a whole genome sequencing-based approach for1 passage
• Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement.1 passage
• Use of forced vital capacity and forced expiratory volume in 1 second quality criteria for determining a valid test.1 passage
• Use of three-dimensional organoids and lung-on-a-chip methods to study lung development, regeneration and disease.1 passage
• Using chest CT scan and unsupervised machine learning for predicting and evaluating response to lumacaftor-ivacaftor in people with cystic fibrosis.1 passage
• Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis.1 passage
• Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study.1 passage
• Utility of measuring FEV0.75/FVC ratio in preschoolers with uncontrolled wheezing disorder.1 passage
• VE-cadherin cleavage in sleep apnoea: new insights into intermittent hypoxia-related endothelial permeability.1 passage
• Validation of Lung EpiCheck, a novel methylation-based blood assay, for the detection of lung cancer in European and Chinese high-risk individuals.1 passage
• Validation of the BRODERS classifier (Benign1 passage
• Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure.1 passage
• Validation of two predictive models for survival in pulmonary arterial hypertension.1 passage
• Validity of the European short list of respiratory diseases: a 40-year autopsy study.1 passage
• Variability of within-breath reactance in COPD patients and its association with dyspnoea.1 passage
• Variable radiological lung nodule evaluation leads to divergent management recommendations.1 passage
• Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis.1 passage
• Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis.1 passage
• Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study.1 passage
• Vascular permeability in the fibrotic lung.1 passage
• Vena cava backflow and right ventricular stiffness in pulmonary arterial hypertension.1 passage
• Ventilator-associated respiratory infection following lung transplantation.1 passage
• Ventilatory response to exercise in cardiopulmonary disease: the role of chemosensitivity and dead space.1 passage
• Viable virus aerosol propagation by positive airway pressure circuit leak and mitigation with a ventilated patient hood.1 passage
• Video-assisted thoracic lobectomy1 passage
• Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova.1 passage
• Violence-related distress and lung function in two longitudinal studies of youth.1 passage
• Vitamin C to Pregnant Smokers Persistently Improves Infant Airway Function to 12 Months of Age: A Randomised Trial.1 passage
• Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37.1 passage
• Volatolomics of breath as an emerging frontier in pulmonary arterial hypertension.1 passage
• Wedge resection and radiofrequency ablation for stage I nonsmall cell lung cancer.1 passage
• What is a COPD exacerbation? Current definitions, pitfalls, challenges and opportunities for improvement.1 passage
• What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion.1 passage
• What is early COPD and why is it important?1 passage
• What is precision medicine?1 passage
• When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases.1 passage
• Which definition of a central tumour is more predictive of occult mediastinal metastasis in nonsmall cell lung cancer patients with radiological N0 disease?1 passage
• Whole-transcriptome sequencing reveals heightened inflammation and defective host defence responses in chronic rhinosinusitis with nasal polyps.1 passage
• Why does oxygen supplementation during exercise training in COPD patients with exercise-induced desaturation not consistently improve exercise capacity?1 passage
• Why we should improve current practice of diagnosing and treating pulmonary large cell neuroendocrine carcinomas in patients with advanced disease.1 passage
• Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases.1 passage
• Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline.1 passage
• World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.1 passage
• World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.1 passage
• Xenon-129 MRI detects ventilation deficits in paediatric stem cell transplant patients unable to perform spirometry.1 passage
• Young and middle-aged adults with airflow limitation according to lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective cohort study.1 passage
• e-Monitoring of Asthma Therapy to Improve Compliance in children (e-MATIC): a randomised controlled trial.1 passage
• miR-146a-5p plays an essential role in the aberrant epithelial-fibroblast cross-talk in COPD.1 passage
• miR-17 overexpression in cystic fibrosis airway epithelial cells decreases interleukin-8 production.1 passage
• microRNA-mRNA regulatory networks underlying chronic mucus hypersecretion in COPD.1 passage
• α1 passage
• αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease.1 passage
• β1 passage
• β2-Adrenergic receptor agonists activate CFTR in intestinal organoids and subjects with cystic fibrosis.1 passage
• ⁹⁹mTc-anti-TNF-α antibody for the imaging of disease activity in pulmonary sarcoidosis.1 passage